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ABSTRACT
TISSUE-RESIDENT MYELOID-DERIVED SUPPRESSOR CELLS MODULATE
IMMUNE HOMEOSTASIS IN HEALTHY ADIPOSE
Katlin B. Stivers
June 10th, 2020
Our goal with this study was to gain insight into the homeostatic immune
cell network in healthy adipose tissue. Specifically, we sought to determine if the
immature myeloid cells found in healthy and inflamed adipose were, in fact, tissueresident myeloid-derived suppressor cells (MDSCs). Using various in vitro and in
vivo methods, we have uncovered a population of CD11b Hi Ly6CHi Ly6G- MDSCs
resident in healthy adipose tissue. To the best of our knowledge this is the first
time that these cells have been investigated and described in healthy adipose
tissue. Systemic MDSC depletion lead to the accumulation of CD4 + CD44+ CD62LTEM in the adipose of otherwise healthy mice and altered the surface markers
expressed by adipose tissue-resident macrophages. Furthermore, we found that
losing MDSCs significantly changed the transcription levels of multiple
immunomodulatory genes in the adipose stromal cell compartment and whole
adipose tissue. Taken together, this suggests that adipose-resident MDSCs are
one of the key players in the adipose tissue immune cell network, preventing
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aberrant, inflammatory TEM proliferation and modulating the suppressive
phenotype of adipose tissue-resident macrophages.
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CHAPTER 1: INTRODUCTION
Adipose Tissue
Adipose tissue (AT) is a loose connective tissue that serves as an energy
storage depot, using fatty acid oxidation reactions to store excess glucose and,
when necessary, release it back into circulation. This tissue has a multitude of
other endocrine, metabolic, and thermoregulatory functions. In mammals, adipose
depots are distributed throughout the body and are divided into two main
categories: brown and white. Mainly found in infants, brown AT (BAT) uses stored
lipids to produce heat and regulate body temperature. In adults the majority of
depots are white adipose tissue (WAT) which can also contribute to
thermoregulation by developing a “beige” phenotype [1]. For the most part
however, WAT stores and releases energy for systemic use in response to
changes in insulin and glucagon levels, respectively.
While adipocytes are the main cellular unit of AT, they are only 20 – 40% of
the total cells found in the tissue, with adipose stromal cells accounting for the
remaining 60 – 80% of cells [2]. In lean, healthy individuals this stromal-vascular
cellular fraction (SVF) contains a wide-array of endothelial cells, mesenchymal
stem cells, pre-adipocytes, and immune cells. Altogether they are integral
regulators of adipose tissue homeostasis. SVF cells promote angiogenesis;
release AT-modulating molecular factors such as cytokines and hormones; and
produce the extracellular matrix elements necessary to maintaining tissue integrity.
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The exact distribution of these cell types differs between adipose depots and may
depend upon its physiological function [3-8]. Compared to visceral AT depots, the
omental AT appears to function more as a tertiary lymphoid tissue than it does an
energy storage depot. For instance, special fat-associated lymphoid clusters in
omental AT act almost as loosely organized germinal centers, where tissue
resident dendritic cells induce antigen-specific B cell responses [9-12]. Over the
last 20 years, we have begun to recognize the importance of the SVF immune cell
compartment in not only driving obesity-induced visceral AT inflammation, but also
maintaining in modulating the day-to-day functions of this tissue [2].

The Essential Role of Inflammation in Healthy Adipose Tissue Homeostasis
Catering to the metabolic needs of an organism is a dynamic process. As
blood glucose levels increase or decrease, adipocytes initiate lipogenesis or
lipolysis reactions to sequester or release energy, respectively. Accompanying the
ebb and flow of lipids being stored or released are requisite fluctuations in the
physical size of adipocytes. Practically, this calls for near constant extracellular
matrix (ECM) remodeling in the adipose to accommodate these physical changes.
Importantly, Wernstedt Asterholm, Tao [13] (2014) found that as adipocytes
initiated either of these metabolic reactions, they simultaneously upregulated their
expression of TNFα. The subsequent inflammatory cascade eventually
precipitated the breakdown of the surrounding ECM, allowing adipocytes to
expand or contract as necessary. This finding was surprising given that this
cascade was observed in healthy, chow-fed mice and that both TNFα upregulation
and AT inflammation are typically associated with obesity. Furthermore, an
2

adipocyte specific inhibition of TLR4-, TNFα-, and IL1β-mediated signaling led to
significant metabolic dysfunction in otherwise healthy animals and enhanced the
metabolic consequences of a high-fat diet compared to WT controls. Implicating
that this inflammatory pathway is physiologically necessary for the maintenance of
healthy adipose tissue homeostasis [13].
Further complicating our perception of inflammatory dynamics in AT is the
ambiguous role of TNFR1 signaling in metabolic health and disease [14]. For
instance, transgenic knockout of TNFR1 gained significantly more weight on a
normal diet than wild-type controls confirming the findings from the aforementioned
study concerning the integral nature of TNF-mediated signaling in maintaining
healthy metabolic homeostasis. When fed a high-carbohydrate diet however,
these TNFR1 knockout mice had improved insulin sensitivity and had reduced
adiposity compared to wild-type controls on the same diet, highlighting the
deleterious effects this same signaling pathway can have in a pathological setting
[14]. Altogether, these studies have brought to light the important role that acute
inflammation, as reflected by TNFα signaling, plays in the day-to-day functions of
this dynamic tissue and calls for a reassessment of the disease-centric way in
which AT inflammation is most often viewed.
Besides the requirement for TNF-α mediated signaling, ECM remodeling
could also be a constitutive source of toll-like receptor (TLR) ligands in the tissue
[15, 16]. By-products of ECM degradation have the potential to be both pro- and
anti-inflammatory, depending upon the microenvironmental context and through
which TLRs they mediate their signals [15]. In AT specifically, these molecules are
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associated with the obesity-induced inflammation [17, 18]. However, even under
normal conditions, AT is constantly being degraded and remodeled, producing
inflammatory-like conditions, yet healthy tissue is not considered to be chronically
inflamed. What prevents these pro-inflammatory molecules and the signaling
pathway involved in AT remodeling from developing into the pathological
inflammation observed in metabolic diseases?

Adipose-Resident Immune Cell Network
According to Wernstedt-Asterholm et al [13, 19], “immunological fitness” is
the saving grace of this tissue. Immunological fitness is a measure of an
organism's (or tissue's) ability to efficiently mount and subsequently resolve an
effective immune response. In this case it applies to the acute TNFα-mediated
inflammatory response required for ECM remodeling in healthy AT. If this
immunological fitness is compromised, then the tissue is no longer able to cope
with these acute inflammatory responses and develops metabolic complications,
as demonstrated by the various transgenic knockout models used in this study
[13].
Going one step further, AT immunological fitness is, at its core, a function
of the tissue-resident immune cell network. This network is inherently
immunomodulatory in healthy AT and most likely evolved as a means to efficiently
quell the intermittent acute inflammatory responses required to properly
accommodate lipid storage and release by adipocytes. Adipose tissue-resident
macrophages (ATMs) make up the largest percentage of these cells by far [20,
21]. ATMs are considered true "tissue-resident" macrophages as they are fetal
4

liver derived [22], do not develop from circulating monocytes, and the population
undergoes self-renewing in situ proliferation [23].
Classically, murine ATMs are defined as F4/80 + CD301+ CD206+ CD11cCD64- and exhibit transcriptional and functional traits associated with “M2-like”
polarization. Recently, the boundaries of this definition have expanded as more
comprehensive, single-cell level studies have uncovered heterogeneity within this
macrophage compartment in healthy AT [24, 25]. Finding surface marker
heterogeneity among this population is not that surprising considering the extreme
sensitivity of macrophages to microenvironmental cues and the dynamic AT
microenvironment. On the other hand, their functional heterogeneity within the
same tissue is unexpected. These cells can perform a multitude of tasks required
for AT to function properly, including clearing dead cellular debris and directing
ECM remodeling efforts [20]. Specific ATM functions may also be dependent upon
their location within the tissue. One study identified a subset of vasculatureassociated ATMs with enhanced endocytic capacity compared to other ATM
subsets [25]. Additionally, ATMs found around hypertrophic adipocytes appear to
act as "clean-up crews” phagocytosing excess lipids released by the adipocyte [26,
27]. Similarly, fatty acids released during weight loss-induced lipolysis are taken
up and stored by ATMs [28]. A common theme among all ATM subsets however,
is that obesity profoundly alters their phenotype and function, steering them
towards a more pro-inflammatory, “M1-like” polarization state [20, 21, 29].
Monocyte-derived macrophages also infiltrate the tissue exacerbating and
sustaining the pro-inflammatory nature of the obese AT microenvironment [20].

5

ATMs maintain their "M2” status in healthy adipose via cytokine signaling
and cross-talk with AT-resident eosinophils and innate lymphoid type 2 cells
(ILC2s) [30]. IL-33 signaling recruits and activates ILC 2s into the adipose, where
they regulate the immunosuppressive phenotypes of many other SVF cell types
[31-33]. Their production of IL-5 and IL-13 is especially important for the resiliency
of the ATM phenotype against inflammatory challenge [30, 34]. IL-5 also recruits
eosinophils into the tissue. Usually associated with promoting rapid type II allergy
responses, these innate granulocytes serve a more regulatory role in adipose.
Eosinophils are one of the primary sources of IL-4 in AT, without which ATMs begin
to switch towards a more pro-inflammatory “M1” phenotype [30, 35].
Adaptive immune cells also participate in the AT immune cell network in the
form of both B and T lymphocytes [2]. The B cell compartment in lean AT is
primarily made up of regulatory B cells that produce IL-10 and influence ATM
phenotype [36, 37], although not much work has been done to elucidate any
additional notes these cells may play in maintaining AT homeostasis.
Much more is known about the T cells found in adipose, albeit through the lens
of obesity. For instance, obesity is perpetuated by the infiltration of both CD4+ and
CD8+ T cells, with a limited TCR repertoire, into the tissue [38]. There are CD4+ T
cells in lean adipose as well. Their origin, function, and specificity however have
yet to be discerned. In mice, depending upon the AT depot, the majority of these
cells exhibit a CD44+ CD62L- effector memory phenotype and are capable of
mounting a Th1-type response upon non-specific co-stimulation [39, 40]. While the
antigen specificity of these memory T cells is unknown, there is growing evidence
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that the WAT may act as a reservoir for pathogen-specific memory T cells [38, 39,
41-48]. For example, Toxoplasma gondii and Yersinia pseudotuberculosis-specific
effector and tissue-resident memory T cells were found in adipose [39]. Moreover,
these populations were self-sustaining, long-lived, and capable of mounting an
effective response upon reinfection. A similar population has also been observed
in human adipose, where HIV positive T cells have been identified even in patients
with undetectable viral loads in circulation [42].
With aging, in both murine and human adipose, the phenotypic distribution of
CD4+ T cells shifts, with the majority transitioning from memory T cells to regulatory
T cells (TRegs) [39, 49, 50]. TRegs accumulate in AT with age. For the most part,
these cells appear to serve a protective purpose in the tissue by influencing the
suppressive phenotypes of other AT immune cells via TGFβ and IL-10 production
[2]. Furthermore, the addition of exogenous TRegs in obese mice alleviates some of
their metabolic symptoms [50]. This may not always be the case however, as
systemic ablation of TRegs actually prevents aging-related metabolic syndromes
from developing [49].
Even though our understanding of the healthy adipose immune cell network is
relatively limited, it is still clear that these cells play a major role in modulating
homeostasis in this tissue and in protecting it from the pro-inflammatory challenges
it faces as a consequence of its dynamic physiologic functions (Figure 1.1).

7

Figure 1.1: Homeostatic Immune Cell Network in Healthy Adipose Tissue.
Dynamic immune cell interplay prevents T cell-mediated adipose tissue
inflammation under normal dietary pressures. ATM: adipose tissue-resident
macrophage. ECM: extracellular matrix. AT: adipose tissue. DAMPs: damageassociated molecular patterns. FFA: free-fatty acids. TCR: T cell receptor. TLR:
toll-like receptor.
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Immunosuppressive Abilities of SVF
The immunomodulatory and tissue remodeling properties of these nonadipocyte cells are currently being investigated for various cell-based antiinflammatory and wound-healing therapeutic applications [51-59]. By studying the
impacts SVF-based cellular therapies have on local immune responses we can
gain insight into the nature of the immunomodulatory microenvironment that these
cells create in their native tissue.
Initially, many of these studies revolved around adipose-derived
mesenchymal stem cells (AD-MSCs) which are derived from SVF following several
days of culture [60]. Similar to bone marrow-derived mesenchymal stem cells ADMSCs possess potent regenerative and immunomodulatory abilities, but are much
more accessible, making them a promising alternative to bone marrow MSC-based
treatments [61-68]. In solid organ transplantation, donor-derived AD-MSCs have
been shown to suppress activated recipient T cell responses and reduce the
severity of acute rejection in rat models of allogeneic liver [69] and kidney [70]
transplantation. Additionally, multiple post-transplant injections of donor-derived
AD-MSCs have been shown to prolong the survival of a vascularized-composite
tissue allograft (VCA) by increasing the number of circulating T Regs and reducing
allograft-infiltrating leukocytes [64, 71]. These cells have also been associated with
the accumulation of immunosuppressive “M2”- like macrophages [72-74]. One
study demonstrated that AD-MSCs reduced aortic inflammation in a murine
aneurysm

model

by

directly

inducing

M2

polarization

[75].

Other

immunomodulatory functions of these cells include suppressing activated B cell
production of immunoglobulin [60], as well as preventing dendritic cell (DC)
9

differentiation and downregulating their expression of co-stimulatory molecules
[63, 67, 76].
Freshly isolated SVF cells also possess substantial regenerative and
immunosuppressive properties, but do not require extensive in vitro enrichment or
expansion to be used therapeutically [51-54]. Compared to AD-MSCs, SVF-based
therapies are equally as effective at treating inflammation and promoting wound
healing [55-57, 59, 77-81]. In a murine model of multiple sclerosis, SVF cells
increased Treg recruitment to sites of inflammation to a similar, if not greater,
degree than AD-MSCs [54, 55]. Clinically, SVF has been used to treat systemic
sclerosis [82], peripheral vascular disease [58], and, in one case, industrial X-ray
injury [83]. In each of these studies, SVF cells reduced circulating levels of
inflammatory cytokines and disease symptom severity in general [58, 82, 83].
Recently, clinical trials performed at the University of Louisville have shown
promising initial results using freshly isolated, autologous SVF cells as a means to
prevent and treat acute VCA rejection [84]. Interestingly, the innate heterogeneity
of the SVF isolate makes it difficult to develop a standardized cellular product for
regulatory approval. However, this same heterogeneity may also be the very
aspect behind the robust therapeutic efficacy of SVF-based treatments as the in
vivo crosstalk that promotes their anti-inflammatory properties in adipose likely
continues after isolation and may preserve their immunomodulatory character
when transplanted into an inflamed microenvironment.
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Myeloid-Derived Suppressor Cells
In our lab, we focused on developing an SVF-based therapy to improve
vascular function following injury. We found that treatment with the SVF improved
vasodilation and reduced immune cell infiltration into the wall of the injured vessel
[85]. Moreover, the SVF isolate lost many of its beneficial effects when the CD11b +
cells were depleted. Further flow cytometric characterization of these CD11b + cells
revealed that a portion also expressed Gr1, a marker typically used to identify
neutrophils. However, given that the SVF utilized in these experiments was
isolated from healthy mice and neutrophil numbers are very low, it is unlikely that
these CD11b+ Gr1+ cells were neutrophils [86]. Another, albeit less conventional,
candidate are myeloid-derived suppressor cells (MDSCs).

MDSCs: An Overview
MDSCs are classically defined as a heterogeneous population of potently
immunosuppressive, CD11b + Gr1+ immature myeloid cells. MDSCs were first
identified as a major contributor to the anti-inflammatory nature of the tumor
microenvironment (TME) and have since been described performing similar
functions in several chronic inflammatory and autoimmune diseases [87-89]. They
have also been shown to promote allogeneic and maternal-fetal tolerance [90-92].
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous collection
of “immature”, or non-terminally differentiated, CD11b + Gr1+ cells that accumulate
at sites of chronic inflammation. They can be further classified into two
subcategories based on their expression of Ly6C and Ly6G: Polymorphonuclear
PMN-MDSCs (CD11b+ Ly6CInt/Low Ly6G+) and Monocytic M-MDSCs (CD11b+
11

Ly6CHi Ly6G-) [93]. Despite their phenotypic heterogeneity, these cells possess
one common trait. They are potently immunosuppressive, targeting both antigenspecific and non-specific inflammatory responses. MDSCs were first identified as
one of the primary cell types responsible for the impaired immune surveillance
observed in the tumor microenvironment (TME) and have since been described
performing similar functions in several chronic inflammatory conditions. As such,
MDSCs are almost exclusively associated with disease and the dysfunctional
resolution of chronic inflammation [89, 94-99]. Since the majority of studies on
MDSCs

revolve

around

the

inhibition

of

tumoricidal

responses,

the

immunosuppressive activity of these cells is often considered to be an abnormal
hijacking of the emergency myelopoiesis response that would not develop under
healthy, steady-state conditions.
Over the last decade evidence has accumulated supporting the idea that
MDSCs may act as the innate immune system's equivalent of regulatory T cells,
protecting tissues from the detrimental effects of chronic inflammation [97]. For
instance, these cells have been identified in chronic inflammatory conditions such
as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis [89, 9499]. In each of those settings, MDSC numbers are correlated with improved
disease outcomes as they downregulate activated T cell responses, promote "M2"
macrophage polarization, and enhance angiogenesis in the inflamed tissue
microenvironment. Additionally, these contentious cells were found to play an
integral role in successful, full-term pregnancies by establishing and maintaining
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maternal-fetal tolerance. Their tolerogenic activities may also play a role is
prolonging graft survival in allogeneic transplantation [90-92].
The diverse nature of both MDSC phenotype and function has made it
difficult to develop a universally applicable definition for these cells. In 2016, MDSC
researchers developed a characterization algorithm (Table 1.1) to rectify this [100].
This strategy uses a combination of phenotypic, biochemical, and functional traits
to differentiate MDSCs from other myeloid cell types such as monocytes and
neutrophils.
Table 1.1: Brontë et al (2016) Algorithm for Characterizing MDSCs.

Defining Characteristics of Myeloid-Derived Suppressor Cells
+

Hi/Low

Quintessential CD11b Ly6C
Ly6G
phenotype

+/-

SSC

Low

surface marker

Immune suppressive activity
Expression of characteristic molecular markers: Arginase, iNOS, IL-10,
TGFβ, IL-4R
Expansion of the myeloid compartment under pathological conditions.

MDSC Effector Mechanisms
The primary effector function of these cells is the inhibition of activated T
cell proliferation through a variety of direct and indirect mechanisms. However,
their influence is not limited to activated T cell responses, as they have also been
found to modulate macrophage phenotype, promote angiogenesis, and induce the
development of regulatory T cells in the periphery [93, 98].
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It's likely that no single MDSC utilizes more than one of these effector
mechanisms at any given time, however the heterogeneous nature of the total
MDSC population may mean that many of these suppressive activities could be
represented within a single TME [101-103]. Moreover, differences between tumor
types strongly affects the cell types and soluble proteins found around the tumor
which means that different tumor types elicit different MDSC responses. The
immature nature of MDSCs could also contribute to their functional plasticity as
they may be able to respond to environmental signals more quickly than a
terminally differentiated cell.

MDSC Effector Mechanisms: Nutrient Deprivation
Pro- and anti- inflammatory responses are often described in terms of
signaling cascades or receptor-ligand interactions. MDSCs however have
developed a potent, somewhat round-about means with which to suppress
proliferative, inflammatory T cell responses. In order to divide, T cells must import
certain amino acids or their precursors from the local microenvironment. MDSCs
can then sequester these resources, preventing T cells from being able to
proliferate further. Arginine and cysteine are the primary targets of this insidious
siege.
Excessive arginine consumption is one of the most straightforward
examples of nutrient deprivation-mediated immune suppression. In the TME,
MDSCs upregulate their expression of induced Nitric Oxide Synthase (iNOS) and
Arginase 1 (Arg1), both of which use L-arginine (L-Arg) as their primary substrate.
The increased activity of these two enzymes eventually depletes L-Arg from the
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surrounding microenvironment. Without access to this essential amino acid,
effector T cells around the tumor cannot proliferate and eventually downregulate
surface expression of the CD3 ζ chain required for proper T cell receptor (TCR)
signaling in response to antigen recognition [104]. This essentially leaves T cells
“blind” to the continued presence of tumor-derived antigens. Eventually, this
prolonged lack of antigen-mediated signaling leads to a significant reduction in
effector T cell activation and proliferation. L-arginine sequestration plays such a
vital role in MDSC-mediated immune suppression that genetic deletion of just one
kind of arginine transporter weakened their ability to inhibit activated T cell
proliferation in vitro [105]. In vivo CAT2-/- mice, which have dysfunctional cationic
amino acid transporter and cannot import arginine, also had reduced tumor growth
compared to control animals which was attributed to a relatively greater number of
tumor-infiltrating lymphocytes and diminished iNOS activity in the MDSCs
themselves [105] (Figure 1.2).
Along with arginine deprivation, MDSCs can also significantly diminish the
amount of cysteine and cystine available in the TME [106]. T cells lack the x cCystine-Glutamate antiporter (xc-) required to import cystine from extracellular
sources. They can, however, acquire cysteine from their local environment via the
Alanine-Serine-Cysteine transporter-1 (Asc-1), a transmembrane neutral amino
acid transport protein. Once inside the cell, cysteine is reduced to the requisite
cystine, essential for continued protein synthesis. In an inflammatory response,
antigen presenting cells (APCs) are thought to be the primary source of
extracellular cysteine taken up by T cells. MDSCs on the other hand only possess
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xc- and do not export release oxidized cysteine back into their surroundings.
Additionally, APC:MDSC crosstalk causes APCs to downregulate expression of
Asc-1 hindering their ability to export cysteine. The rapid uptake and consumption
of cystine by MDSCs combined with a reduced rate of cysteine export by APCs
drastically impacts the amount of cysteine available for use by proliferating,
effector T cells. Without an available pool of this amino acid, activated T cells
downregulate expression of the CD3 ζ chain resulting in proliferative arrest (Figure
1.2).

MDSC Effector Mechanisms: Oxidative Stress
Apart from the over consumption of L-Arg, MDSCs use iNOS and Arg-1 to
manipulate inflammatory immune responses by inducing oxidative stress within
the TME (Figure 1.3). Co-expression of these enzymes, along with NADPH
oxidase, allows MDSCs to produce reactive oxygen (ROS) and nitrogen species
(RNS) that have various suppressive effects [107]. These induce downstream
effects that can be divided into two broad categories: signal interruption and
impaired trafficking. MDSC-induced oxidative stress can manifest in several ways
since ROS and RNS do anything from directly damaging the tissue to influencing
the folding of individual proteins. In terms of T cell-specific impacts, PMN-MDSCproduced hydrogen peroxide reduces T cell expression of the CD3 ζ chain [108]
(Figure 1.3 a), while M-MDSC-produced peroxynitrite incapacitates IL-2 receptors
via nitrosylation [109] (Figure 1.3 b). Either way T cell sensitivity to various
activation signals is greatly diminished. Similarly, peroxynitrite can interfere with T
cell migration by nitrosylating CCL-2 on the surface of T cells. This alters the
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conformation of this chemokine, effectively preventing the cell from migrating into
the tumor itself [110] (Figure 1.4 a).

MDSC Effector Mechanisms: Cytokines and Direct Cell-Cell Interactions
Although Ros and RNS are powerful mediators of immune suppression,
they are not the only molecular tools MDSCs have at their disposal. These cells
use both surface and soluble proteins to downregulate the inflammatory, antitumor responses of various cell types in the TME. ADAM17 cleaves L-selectin
(CD62L) on the surface of T cells, downregulating its expression and preventing
their trafficking to the draining lymph nodes [111] (Figure 1.4 b). MDSCs can also
induce T cell apoptosis by expressing Gal9 on their surface, which interacts with
TIM3 on T cells [112] (Figure 1.4 b). MDSC-produced cytokines can also directly
influence the pro-inflammatory nature of cells in the TME (Figure 1.5). There is
evidence that membrane bound TGF-β on MDSCs prevents NK cells from
mounting tumoricidal responses [113]. MDSCs also produce IL-10 which steer
macrophage polarization towards the tumor preserving, immunosuppressive "M2"
phenotype [114, 115]. Additionally, IL-10 production by MDSCs reduces TLR4
expression on the surface of dendritic cells (DC). Without this pattern recognition
receptor, DCs cannot recognize tumor-induced tissue damage and stop producing
IL-12 which would otherwise be used to promote pro-inflammatory, antigenspecific T cell responses [115].
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MDSC Effector Mechanisms: MDSCs and T Regs
MDSCs within the TME directly modulate the functional phenotypes of
various innate immune cells. This influence extends to adaptive immunity as well,
going beyond simply preventing antigen-specific, pro-inflammatory T cell
responses. MDSCs have the ability to activate and induce T Reg differentiation in
the periphery and activate natural TReg already is circulation [107]. The exact
mechanisms behind this have yet to be uncovered, but there are several potential
candidates. These include the production of cytokines such as IFNγ, IL-10, and
TGFβ [116]; CD40-CD40L-mediated cell-cell interactions [117]; and their
increased arginase activity [118]. No matter what the mechanism is behind
MDSC:TReg interactions, it is clear that induction or a clonal expansion of these
cells is a powerful tool that MDSCs can use to manipulate anti-tumor responses in
their microenvironment.
Despite the ambiguous nature of these cells, one thing remains clear,
wherever there is prolonged chronic inflammation or the persistent need for
immune tolerance, suppressive myeloid cells accumulate. This strongly supports
the idea that these cells are less of a pathological consequence to an immune
insult and more of a physiologically normal innate response to prevent further
inflammation-induced tissue damage.
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Figure 1.2: MDSC-mediated nutrient deprivation downregulates activated T
cell proliferation in the tumor microenvironment. MDSCs disrupt
cystine/cysteine homeostasis and overconsume arginine in their local
microenvironment, preventing T cells from acquiring these amino acids, essential
for their continued proliferation. MDSC: myeloid-derived suppressor cell. TAM:
tumor-associated macrophage.
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Figure 1.3: MDSCs use oxidative stress responses to prevent T cell
activation and subsequent proliferation in the tumor microenvironment. (a)
NADPH oxidase and iNOS activity increases hydrogen peroxide levels in the
microenvironment, prompting T cells to downregulate CD3ζ expression and
ultimately disrupting their ability to respond to antigen. (b) Peroxynitrite deforms
surface proteins such as T cell receptors (TCR) and IL-2R. In the absence of
continued IL-2 signaling and antigen recognition. T cell proliferation grinds to a
halt. MDSC: myeloid-derived suppressor cell.
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Figure 1.4: MDSCs disrupt lymphocyte trafficking into and out of the tumor
microenvironment. (a) MDSC-mediated nitrosylation of CCL2 interrupts the
signaling pathway that recruits CD8+ cytotoxic T cells into tumor tissue. (b) MDSCs
interact directly with T cells to prevent their migration into the lymph nodes by
disrupting CD62L expression or promoting cell death. MDSC: Myeloid-derived
suppressor cell. TCR: T cell receptor.
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Figure 1.5: Immunomodulatory effects of MDSCs on innate immune cells. In
addition to T cells, MDSCs can manipulate the inflammatory responses of other
cells in the tumor microenvironment using contact-dependent and independent
mechanisms. MDSC: myeloid-derived suppressor cell. TAM: tumor-associated
macrophage. DAMPs: damage-associated molecular pattern. TCR: T cell
receptor.
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MDSC Ontogeny
Since their discovery the possible origins of MDSCs has been a subject of
speculation. The prevailing hypothesis among MDSC biologists today suggests
that generation of MDSCs in pathology occurs in two steps. First there is an
expansion of the immature myeloid cell (IMC) population, subsequently followed
by an "activation" signal leading to their acquisition of suppressive characteristics.
This model is based upon the emergency and extramedullary myelopoiesis which
is a result of the non-resolving or chronic inflammation induced by conditions such
as cancer, sepsis, or autoimmunity [93, 119]. The prolonged inflammatory
pressures at these sites promotes the migration of IMCs from the bone marrow to
replace exhausted or dead myeloid populations at the origin of the insult. Additional
expansion of this IMC population can occur in the spleen in response to secondary
tumor-derived signals. It's this secondary signal, usually in the form of proinflammatory cytokines (IFNγ), Th2-associated cytokines (IL-4 or IL-13), or TLR
ligands (DAMPs), that causes the cells to develop suppressive functional abilities
[99].
An alternative hypothesis concerns the nature of the secondary, "activation"
signal. In this model abnormally prolonged inflammation still induces emergency
and extramedullary myelopoiesis, mobilizing and expanding IMCs. In this case
however, the secondary signal arrests any further maturation of these cells [120123]. Here it is assumed that the suppressive activities of MDSCs are actually an
inherent quality possessed by all IMCs which differentiate into macrophages, DCs,
and neutrophils so quickly under steady-state conditions that these abilities are of
little consequence.
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The exact "expansion" and "activation" signals that lead to the accumulation
of MDSCs vary greatly depending upon the condition and even differ among tumor
models. These cells are highly susceptible to signals in their microenvironment and
will attune their gene expression and function in response [101]. In practice this
means that MDSCs isolated from two different kinds of tumors may have starkly
different transcriptional profiles, making it difficult to accurately identify a signature
“MDSC-inducing” signaling pathway. There are some candidate pathways and
transcription factors however that have been linked to their myeloid suppressor
phenotype (Figure 1.6). STAT3 activation is found almost universally within any
MDSC population being characterized. IL-1β, IL-6, IL-10, GM-CSF, and G-CSF
produced in the TME have all been associated with inducing STAT3-mediated
transcription of Nox2 and Arg1, both of which regulate ROS-based immune
suppression or the expansion of MDSCs at the tumor site [107]. IL-1β and IFNγmediated signaling through STAT1 in addition to IL-4 and IL-13-mediated
activation of STAT6 also promote MDSC immunosuppressive activity by
upregulating Nos2, Arg1, and Nox2 expression. STAT-dependent gene
transcription also contributes to immature myeloid cell migration from the bone
marrow, MDSC differentiation, and their accumulation at the tissue site via Bcl2l1
and S100a8/9 expression induced by GM-CSF signaling through STAT3 and
STAT5 [124].
Common among many MDSC researchers who subscribe to the classic
"two-signal" model, is a steadfast belief that MDSCs arise from an abnormal
response to pathologically prolonged or non-resolving inflammation. In other
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words, there is an inherent defect that has inappropriately sustained a proinflammatory response and it's only under these conditions that MDSCs develop
[97, 100]. Central to this is the assumption that MDSCs are fundamentally distinct
from other immune cells, such as TReg and “M2” macrophages, that accumulate
during the resolution phase of a normal immune response to promote wound
healing and prevent further inflammation-derived tissue damage.
There is some evidence that this way of thinking about MDSCs may not be
quite as accurate as it was once considered to be. For instance, MDSCs have
recently been shown to be essential for the maintenance of maternal-fetal
tolerance. If MDSCs were generated by a defective immune response, then they
would not be so closely associated with normal, successful pregnancies [90, 97].
MDSC recruitment during sepsis may provide additional evidence for this. These
cells may impair bacteria-clearing immune responses at later time points, but their
presence in early stages of septicemia prevents the detrimental tissue damage
caused by the extreme inflammatory responses this condition elicits [93, 125]. With
this in mind, some researchers have begun reexamining the nature of this original
“two-signal” model with a few even rethinking what kinds of cells should or should
not be considered MDSCs [93]. As Millrud, Bergenfelz [93] stated in their 2016
review On the origin of myeloid-derived suppressor cells, “An important issue
concerning MDSC generation to remember is that tumors do not invent new
biology, they highjack existing mechanisms."
Along these lines, recent studies on the nature of neutrophils have shown
that, once activated, these cells can live much longer than we originally thought
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and can develop either a pro- or anti-inflammatory phenotype based upon their
surroundings. Initially these cells were separated from PMN-MDSCs using a
density gradient since they were significantly more granular [126]. New evidence
indicates however, that degranulated neutrophils are less dense and settle at a
similar level as PMN-MDSCs following density centrifugation. This has led some
researchers to hypothesize that a portion of the heterogeneous subset we classify
as PMN-MDSCs, may actually be degranulated, immunomodulatory tumorassociated neutrophils [100].
As for the generation of M-MDSCs I prefer the model proposed by Millrud,
et al. (2016) in the review quoted above. Like the classic hypothesis, theirs also
consists of two signals, however instead of the "expansion" and "activation" of
IMCs, they propose a model whereby monocytes are "recruited" and
"reprogrammed". Damage or pathogen associated molecules trigger toll-like
receptors on the surface of monocytes, recruiting these cells out of circulation.
Once in the tissue or tumor site, these cells continue to encounter TLR agonists in
addition to immunomodulatory signals such as IL-10. This combination of pro- and
anti-inflammatory stimuli “reprograms” the monocyte, causing it to acquire immune
suppressive functions [93]. The “recruit and reprogram” model is particularly
appealing as it places M-MDSCs on a similar level as any other cell type that gets
reprogrammed by tumor-derived signals. In either case, it is becoming increasingly
clear with each new non-cancer-centric MDSC study that it is time to reassess not
only our model of how MDSCs are generated, but also our one dimensional,
pathology-oriented idea of these complicated cells.
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Figure 1.6: Candidate signaling cascades contributing to MDSC
accumulation and suppressive phenotype. The plasticity of MDSCs makes it
difficult to precisely define a single “MDSC-inducing” signaling profile, there are
some however that have been linked with various aspects of MDSC biology.
DAMPs: danger-associated molecular patterns.
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MDSCs in Healthy Tissues
Our understanding of MDSC biology has greatly expanded since they were
first described almost 20 years ago. Despite the growing list of conditions in which
MDSCs play a beneficial role, the majority of studies on their biology is still done
within the realm of cancer. Furthermore, the assumption that these cells only arise
from pathologically induced abnormal maturation still permeates the field. CD11b +
Gr1+ cells found in healthy tissues are often dismissively classified as immature
myeloid cells without further functional studies since it’s assumed that the
immunosuppressive activity of those cells only arises as a consequence of
inappropriately prolonged emergency myelopoiesis or chronic inflammation.
The endurance of this belief may be strongly linked to their original
discovery in the tumor microenvironment and the profound role they play in priming
it for optimum immune evasion. If these cells had been discovered under different
conditions, investigations may not have been so narrowly focused. For instance,
the immunosuppressive nature of tumor-associated macrophages is considered a
pathological consequence of the tumor microenvironment on these cells, but
macrophages in and of themselves are not associated solely with disease. Even
immunosuppressive "M2-like” macrophages are seen as physiologically normal in
steady-state conditions. Testing the functional activity of macrophages isolated
from healthy tissues is important and, for the most part, seen as a necessary step
in characterizing a novel population.
The explosion of CD11b+ Gr1+ cells under chronic inflammatory pressures
should also not be used to justify our disregard for the effector functions of these
cells in steady state. Knowing that T cells clonally expand following antigen
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recognition does not prevent CD3+ CD4+ cells from being recognized as bona fide
T cells when they're isolated from healthy tissues.
Molecular signals within the surrounding tissue have a profound impact on
macrophage and T cell differentiation and functional phenotype. It’s thought that a
similar dynamic occurs with MDSCs within the tumor microenvironment, as
MDSCs isolated from different types of tumors often exhibit different patterns of
gene expression and use different mechanisms to suppress inflammatory
responses [102]. Furthermore, several studies over the last few years have
revealed more and more non-tumor associated instances that give rise to MDSCs
[90] [90-92]. In autoimmune diseases such as rheumatoid arthritis, MDSCs
suppress inflammatory T cell responses and drive T Reg induction via their
production of IL-10 [127]. MDSCs have also been identified outside the realm of
pathology altogether. Although the situations described thus far represent
physiologically normal, perturbations of tissue homeostasis such as becoming
pregnant or being recently born. In each case MDSCs play a protective role against
fetus-directed and overactive immune responses respectively [90, 128]. To me,
this all indicates that the suppressive MDSC phenotype develops more from the
cues an immature myeloid cell encounters within a particular microenvironment
than as a consequence of the pathology itself. Taken one step further, this implies
that any tissue containing the appropriate combination of molecular signals could
give rise to its own population of MDSCs.
As the list of MDSC-inducing conditions grows and begins to include
physiologically normal situations like pregnancy [90], MDSC biologists need to
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reexamine their perceptions of these cells. Perhaps even consider the possibility
that they are alternatively activated monocytes and neutrophils involved in
mediating tissue homeostasis and repair, just like their alternatively activated
macrophage counterparts.

The MDSC-inducing Potential of Healthy Adipose Tissue
Both leptin knockout and high-fat diet-fed mice develop chronic, low-grade
adipose tissue inflammation, which leads to the accumulations of MDSCs [129].
Similar to what is seen in autoimmune-induced inflammation these cells play a
protective role in the tissue by offsetting the metabolic dysfunction associated with
obesity [129, 130]. Intriguingly the studies that first identified these cells in inflamed
adipose also describe a population of CD11b + Gr1+ cells in the adipose of their
normal diet-fed, negative control mice. Unfortunately, the immunomodulatory
functions of these cells were never tested, as it was assumed that cells with these
surface markers did not develop immunosuppressive capabilities in the absence
of pathological pressures. However, the microenvironments of tumors and healthy
adipose tissue share many common elements as they both have a propensity for
employing a network of cellular and molecular players to promote and sustain
robust anti-inflammatory conditions. Surprisingly, many of the shared elements of
this network are involved in the recruitment of MDSCs by tumors. Therefore, if we
assume that an MDSC acquires its immunomodulatory nature as a consequence
of signals from its surroundings and not pathology itself, then it’s likely that the
CD11b+ Gr1+ cells in the adipose of their negative controls would have inhibited
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activated T cell responses. Table 1.2 highlights some of the key similarities
between tumors and healthy adipose tissue.
On a macro level, both tumors and adipose are dynamic tissues where both
pro- and anti-inflammatory stimuli are found. The coexistence of these
diametrically opposed signaling molecules are essential elements in the “Recruit
and Reprogram” model of MDSC generation [93]. From a cell network point of
view, tumor-associated macrophages (TAMs) are one of the driving forces behind
MDSC recruitment and retention at the tumor site. TAMs provide IL-10 which
reprograms recruited monocytes into suppressive MDSCs. Additionally, IL-10
produced by MDSCs promotes the “M2” phenotype of TAMs, establishing a
mutually beneficial feedback loop. This allows for more MDSCs to accumulate and
strengthen the immunosuppressive nature of TAMs. In healthy adipose tissue, the
similarly “M2” skewed tissue-resident macrophage (ATM) population produces IL10 [20, 131, 132] which is a necessary component of the anti-inflammatory AT
environment.
T cells play a critical role in creating the optimum niche for MDSCs in the
tumor microenvironment. For instance, IFNγ and TNFα produced by tumorinfiltrating effector T cells provide the chronic myelopoiesis and the eventual
recruitment of immature myeloid cells (IMCs) to the tumor site [133]. Meanwhile,
induced regulatory T cells prime the microenvironment with IL-10 and TGFβ
contributing to the pool of anti-inflammatory cytokines that can reprogram IMCs
into MDSCs [134, 135]. Both effector memory and regulatory T cells are present
in healthy adipose tissue.
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Some of the other players in the adipose immune cell network such as ILC2s and NKT cells are also involved in establishing the immunosuppressive
conditions in the tumor microenvironment. In both tumors and adipose these cells
promote “M2” polarization of the resident macrophage populations via IL-13
production [136-138]. This cytokine can also contribute to the suppressive
phenotype

of

MDSCs.

Collectively,

these

similarities

with

the

tumor

microenvironment make healthy adipose tissue a likely niche for MDSCs to
accumulate.
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Table 1.2: Similarities Between the Tumor & Adipose Microenvironments.

Cell Type

Tumor
Microenvironment
o

Macrophages

Regulatory T Cells
(Treg)

Effector / Effector
Memory T Cells

o

Produce IL-10 & TGFβ
which promote “M2” TAM
& MDSC suppressive
phenotypes

o

Produce IFNγ & TNFα
which recruit IMCs to
tumor site
IL-10 & TGFβ suppress
effector responses

o

o
o

NKT Cells

o

o
o

o

o

o
ILC2s

IL-10 feedback loop
between Treg & MDSCs
strengthen “M2”
phenotype
IL-10 promotes monocyte
reprogramming into
MDSCs

Adipose Tissue
Microenvironment

IL-25 & IL-13 induce Th2
T cell responses which
are protumoral
Recruited by stromal cell
produced IL-33
Produce IL-13 that
promotes protumoral type
2 immune responses.
IL-10 & IL-13 promote
“M2” TAM & MDSC
suppressive phenotypes
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o

o
o
o
o
o

o
o

IL-10 from Tre & NKT
cells promotes “M2”
phenotype
IL-10 sustains
suppressive nature of
other AT immune cells
Population grows over
time
Produce IL-10 & TGFβ
which promote “M2” ATM
polarization & suppress
TEM responses
Primarily quiescent
memory phenotype
Mount rapid IFNγ & TNFαdriven inflammatory
responses
Produce IL-13 & IL-5
which promote “M2” ATM
phenotype
Aide in eosinophil
recruitment via IL-5
Recruited to AT by IL-33
Produce IL-10, IL-12, and
IL-13 which contribute to
“M2” ATM phenotype
IL-12 contributes to
maintenance of Treg
population.

CHAPTER 2: METHODS & MATERIALS
Animals
C57BL/6J mice were purchased from Jackson Laboratory [Bar Harbor, ME,
USA] or bred in-house. Unless stated otherwise all reported findings were from 1026-week-old male mice. All animal studies were performed under protocols
approved by the University of Louisville Institutional Animal Care and Use
Committee and complied with the National Institutes of Health Guidelines for the
Care and Use of Laboratory Animals.
Stromal Vascular Fraction Isolation
Perigonadal fat pads (epididymal or uterine horn) were harvested from 5-10
mice and collected in sterile 0.1% BSA solution. In a sterile petri dish, the pooled
adipose tissue was manually homogenized with scissors. 1mL of Digestion Buffer
(2mg Collagenase [Worthington Biochemical Corporation; Lakewood, NJ, USA],
1mg DNase [Sigma-Aldrich; St. Louis, MO, USA], 1mL 0.1% BSA) per milliliter
adipose tissue was added to the homogenized tissue. The total solution (adipose
+ digestion buffer) was collected in a 50mL conical vial containing a stir bar and
digested at 37° C in an Envirogenie (37.5 rpm) for 35 minutes. Following digestion,
the contents of the tube were transferred to fresh 15mL conical vials and
centrifuged for 4 minutes at 550 x g. The supernatant was discarded; the cell pellet
was resuspended in 0.1% BSA; and centrifuged once again for 3 minutes at 400 x
g. Cell were resuspended in 0.1% BSA and passed through a 20μm filter.
Some experiments required SVF cells to be isolated from individual mice,
in order to fully appreciate the variability that exists in terms of adipose stromal cell
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make-up. For these isolations, the epididymal fat pads were collected from each
animal in 3mL 0.1% BSA and kept at 4° C until they were processed. The tissue
was then transferred to a fresh 5mL tube where it was manually homogenized with
scissors. One volume of Digestion Buffer was added, and the tubes were
incubated at 37° C in a tube rotator for 35 minutes. When processing multiple
samples at once, homogenization and incubation was staggered to ensure even
digestion times for each sample. Following digestion, cold 0.1% BSA was added
to each tube. Samples were centrifuged at 550 x g for 4 minutes. Supernatants
were discarded, and the pellet was transferred to a new 5mL tube. After
resuspension, the cells were centrifuged once more at 400 x g for 3 minutes. Fresh
0.1% BSA was added to the washed cells which were then filtered through a 20μm
filter cup [pluriSelect Life Science; Leipzig, Germany]. To ensure maximum cell
yield, the tube was rinsed twice and the filter once with 5mL 0.1% BSA. This
individual cell isolation protocol produced cell yields and population distributions
that were comparable to our pooled SVF isolation protocol.

Flow Cytometry Staining for Analysis
Adipose stromal cells and splenocytes were incubated in Fc block for 10
minutes in the dark, at room temperature. Cells were stained with appropriate
monoclonal antibodies for 20-30 minutes at room temperature. Table 2.1 contains
the antibodies included in each staining panel used in this study. Intracellular
staining for Foxp3 and Ki-67 was performed using Foxp3/Transcription Factor
Staining Kits [eBioscience; San Diego, CA, USA] according to the manufacturer’s
instructions. Data was collected on an LSR II cytometer [BD Biosciences; Franklin
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Lakes, NJ, USA] and analyzed with FlowJo software [Tree Star; Ashland, OR,
USA]. Compensation beads [BD Biosciences] were used for data collection, but
compensation was manually adjusted during analysis to account for the
autofluorescent nature of adipose stromal cells.
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Table 2.1: List of Antibodies Used in Flow Cytometry Panels.
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Cell Sorting
For sorting adipose-derived MDSCs (aMDSCs), total adipose stromal cells
were stained with CD11b APC [Miltenyi Biotec; San Diego, CA, USA], Ly6C FITC
[VWR; Radnor, PA, USA], and Ly6G PE-Cy7 [VWR]. CD11b Hi Ly6CHi Ly6GSSCLow cells were then sorted by the University of Louisville Microbiology and
Immunology Flow Cytometry Core Facility on a FACS Aria III [BD Biosciences]
(Figure 2.1 a). We found that stresses inherent to the sorting process negatively
impacted the suppressive phenotype of FACS-isolated MDSCs. However, if the
cells were allowed to recover for 4-5 hours at 4°C they regained their
immunomodulatory functionality [139, 140] (Figure 2.2).
For sorting adipose tissue T cells and macrophages, total adipose stromal
cells were stained with CD11b PE [Miltenyi Biotec], Ly6C FITC [VWR], CD4 APCCy7 [VWR], MHC-II PE-Cy7 [VWR], and CD301 AlexaFluor647 [Bio-Rad;
Hercules, CA, USA]. Both CD11b+ Ly6C+ CD301+ MHC-II+ adipose macrophages
(Figure 2.1 a) and CD11b- CD4+ adipose T cells were collected (Figure 2.1 b).
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Figure 2.1: Cell sorting strategies for FACS isolation of SVF subpopulations.
(a) MDSC & adipose macrophage sort strategy (b) Adipose tissue T cell sort
strategy.
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Figure 2.2: FACS isolated aMDSCs require a brief rest period before use in
proliferation assays. Sorted aMDSCs were either immediately resuspended in
RPMI and plated (non-rested) or left in sort buffer at 4° C for 3 hours before being
resuspended in media and plated (rested). aMDSCs were co-cultured with
αCD3/αCD28 activated MACS-enriched T cells. After five days T cell proliferation
was assessed by measuring Abs at 450nm. Abs values within each experiment
were normalized to create a PI relative to the mean Abs of αCD3/αCD28stimulated MACS-enriched T cells. Finally, each co-culture was then analyzed via
flow cytometry to determine what proportion of the remaining live cells was made
up of aMDSCs. (a) The frequency of remaining aMDSCs in each co-culture versus
activated T cell proliferation (Proliferation Index). Each circle represents an
individual well. (b) αCD3/αCD28-stimulated T cell proliferation following five-day
co-culture with non-rested (Blue) or rested (Pink) aMDSCs.
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T Cell Proliferation/Suppression Assays
Adipose stromal cells were processed and isolated as described from 10,
16 – 20-week old, male mice. Cells were then stained and sorted as described
above. While the sorted cells were resting, spleens from 2-3 mice were manually
disrupted and passed through a 100 μm cell strainer. The single cell suspension
was washed twice with sterile HBSS and filtered a final time through a 70 μm cell
strainer. Total splenocytes were counted, then enriched for T cells using a negative
selection magnetic bead separation kit [Miltenyi Biotec] according to the
manufacturer’s instructions. MACS-enriched T cells and sorted adipose-derived
CD11bHi Ly6CHi Ly6G- SSCLow cells were resuspended in media [RPMI 1640
supplemented with 10% FBS, 2-Mercaptoethanol, Pen/Strep, Fungizone, and
EDTA] and plated at a 1:1 ratio in a 96-well culture plate. The final culture volume
in each well was 100uL. Some wells were coated with 1ug/mL αCD3 and 3ug/mL
αCD28 to activate the T cells. Each culture condition was performed in triplicate.
Due to the small number of CD11bHi Ly6CHi Ly6G- cells obtained from each
sort, the use of traditional flow cytometry or radiation-based proliferation assays
was not feasible, as the low cell numbers made it difficult to reliably obtain
repeatable results with these standard methods (See detailed explanation under
Chapter 3: Experimental Challenges & Model Development). As an alternative,
T cell proliferation was assessed, after 5 days, using a colorimetric MTT assay,
according to the manufacturer’s instructions [TetraZ Cell Proliferation Kit;
BioLegend; San Diego, CA, USA] (Figure 2.3). Suppression of T cell proliferation
was determined by establishing a “Proliferation Index” (PI) where the absorbance
value obtained from each co-cultured well was divided by the mean absorbance of
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activated T cells or splenocytes alone. Mean PI values were calculated for each
co-culture condition. Values greater than 1 indicated an increase in T cell
proliferation, while PI values significantly less than 1 indicated that T cell
proliferation had been suppressed. To further confirm that the differences in
absorbance values between co-culture conditions were due to differences in T cell
proliferation and not the result of variations in metabolic activity, we stained the
cells with CD4 and CD8 following the final MTT measurement, then determined
the absolute number of T cells in each well using flow cytometry using Accucount
Beads [Spherotech; Lake Forest, IL, USA].
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Figure 2.3: Schematic of TetraZ-based MTT assay workflow. Naïve
splenocytes or MACS-enriched T cells are cultured by themselves, activated with
plate-bound αCD3/αCD28, or activated and co-cultured at a 1:1 ratio with either
Full SVF, aMDSC-depleted SVF (ΔaMDSCs), or sorted aMDSCs. After 3 – 5 days,
10μL of TetraZ reagent is added to each well and returned to the incubator for 4 –
6 hours. After incubation, absorbance is measured at 450nm.
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RNA Isolation, RT-PCR & qPCR
RNA for this study was isolated with the RNeasy Mini or Micro Kits [Qiagen;
Germantown, MD, USA] depending on the size of the sample. Prior to RNA
isolation, cells and tissue lysates were homogenized with Qiashredder columns
[Qiagen]. Lysates from whole adipose tissue were collected via Qiazol [Qiagen]
and chloroform extraction. They were homogenized with the Qiashredder columns
before RNA purification with the RNeasy Mini Kit [Qiagen]. cDNA synthesis was
performed using SuperScript IV VILO with ezDNase [Thermo Fisher Scientific;
Waltham, MA, USA]. SYBR Select Master Mix [Thermo Fisher Scientific] was used
to perform qPCR on a StepOne Plus thermocycler [Applied Biosystems; Foster
City, CA, USA]. In some cases, amplified DNA products were visualized by
agarose gel separation. IL-2 amplification was performed with the Mm_Il2_1_SG
QuantiTect Primer Assay kit [Qiagen] while all other mouse primers were designed
and purchased through IDT [Integrated DNA Technologies; Coralville, Iowa, USA].
Primer sequences are listed in Table 2.2.
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Table 2.2: List of qRT-PCR primers.
Target Gene

Forward (5’  3’)

Reverse (5’  3’)

Arg1

CTCCAAGCCAAAGTCCTTAGAG

AGGAGCTGTCATTAGGGACATC

Ifng

ATCTGGAGGAACTGGCAAAA

TTCAAGACTTCAAAGAGTCTGAGG

Il10

AATAAGCTCCAAGACCAAGG

CAGACTCAATACACACTG

Il33

ATGGGAAGAAGCTGATGGTG

CCGAGGACTTTTTGTGAAGG

Pparg

GAAGCGGTGAACCACTGATATT

GAGAGGTCCACAGAGCTGATT

Tbp

CTACCGTGAATCTTGGCTGTAA

GTTGTCCGTGGCTCTCTTATT

Tgfb1

GGACTCTCCACCTGCAAGAC

GACTGGCGAGCCTTAGTTTG

Tnfa

GAGAAAGTCAACCTCCTCTCTG

GAAGACTCCTCCCAGGTATATG
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In Vivo MDSC Depletion
16-week-old male mice were injected subcutaneously with 15 μg g -1 of
purified Gr-1 (αGr1) antibody [Clone: RB6-8C5] or Rat IgG2b isotype control
[Clone: LTF-2] [BioXCell; West Lebanon, NH, USA], every 3-4 days throughout the
duration of the experiment. Animals were weighed at each injection to monitor for
any negative metabolic effects of the treatment. Both epididymal fat pads were
collected at the end of the experiment (no more than two days after the final
injection). Spleens were collected from each mouse to verify successfully MDSC
depletion and check for any other systemic effects induced by the treatment.

ELISAs
T cell proliferation assays were set up as described above. After two days,
50 – 100 μL of supernatant was collected from each well and stored at -80° C in a
separate 96-well plate. A matching volume of media was added back to the cocultures and the plate was returned to the incubator for the duration of the
experiment. Later, frozen supernatants from multiple experiments were thawed at
room temperature and centrifuged to remove any suspended particulate matter.
Cytokine specific ELISA kits were then used to test the supernatants for the
presence of either IL-10 [Mouse IL-10 Quantikine ELISA Kit; R&D Systems;
Minneapolis, MN, USA] or TGFβ [Mouse/Rat/Porcine/Canine TGF-β 1 Quantikine
ELISA Kit; R&D Systems] according to the manufacturer’s instructions.

46

Statistical Analysis
Statistical analyses were performed with SigmaPlot 14 [Systat Sofware, Inc;
San Jose, CA, USA]. Absorbance values obtained from the T cell suppression
assays were analyzed using a one-way ANOVA followed by Holm-Sidak post hoc
tests. All comparisons between untreated and αGr1-treated animals were
analyzed using a Student’s unpaired t-test. Data are presented as means ± SEM
unless otherwise indicated. Correlation strength was determined by calculating the
Pearson’s coefficient, where R values of 0.7 – 1.0 were considered “Strong”
correlations and values between 0.5 – 0.7 were considered “Moderate”.
Significance of these correlations were determined using these R values. For all
statistical analyses, the significance level was set at P ≤ 0.05.
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CHAPTER 3: EXPERIMENTAL CHALLENGES & MODEL
DEVELOPMENT
Several aspects of this project presented some unique experimental
challenges that necessitated the adaptation and development of new models.
These challenges fell into one of two general categories: culturing ultra low
numbers of cells or working with a complex heterogeneous peripheral tissue.

T Cell Proliferation Assays: Adaptations for working with small cell
populations.
Initially we decided to use CFSE dilution to assess T cell proliferation in our
mixed cell co-cultures. For these assays splenocytes were processed as described
above, then resuspended to 40×106 cells/mL. The CFSE stain was reconstituted
at room temperature according to the manufacturer’s instructions. A 5μM working
solution was made up by adding 5μL of the stock CFSE to 10mL sterile HBSS. 1
volume of this solution was added to the splenocytes (i.e. 2mL of splenocytes at
40×106 cells/mL were stained with 2mL CFSE working solution). Cells were
incubated for 5 minutes in a 37°C water bath, removed promptly and incubated
another 5 minutes at room temperature, protected from light. The reaction was
quenched with enough HBSS-2% FBS to fill the tube, then mixed thoroughly by
pipetting. Cells were centrifuged at 350 x g for 5 minutes, washed with HBSS-2%
FBS, and spun once more with the same settings. After the final wash, cells were
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resuspended in 5mL RPMI-10% FBS and counted using the nucleocounter. The
splenocytes were then analyzed on the flow cytometer to check if the cells had
been sufficiently stained. The percentage of CD4+ and CD8+ splenocytes was also
determined at this time. This allowed us to properly resuspend the splenocytes
according to number T cells so that they could be co-cultured with the sorted
aMDSCs at a 1:1 ratio of T cells to aMDSCs.
After 5 days, each co-cultured well was stained with CD4 and CD8 so that
CFSE dilution could be examined specifically in the T cells. Cells were stained in
the 96 well plate, resuspended in 200μL of wash buffer, and transferred to a
microtube for analysis. The wells were rinsed once more with 200µL of wash buffer
which was also transferred to the corresponding microtube.
Our pilot experiments using this protocol had mixed success due to
inconsistent T cell activation. Without this positive control, we were unable to
determine whether or not our adipose-derived cells were affecting T cell
proliferation. After verifying our reagents, we concluded that the concentration of
T cells in each well was too low to establish a sufficiently robust IL-2 and IL-4driven autocrine feedback loop to sustain a proliferative T cell response. Ultimately
it was this observation that motivated our search for an alternate method to detect
changes in T cell proliferation that might have increased sensitivity to more subtle
changes in T cell numbers. We also worked to optimize our culture system to
ensure consistent T cell activation with each experiment.
Since a demonstrated ability to suppress inflammatory T cell responses is
the “gold standard” for MDSC characterization we needed to optimize our culture
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system to ensure consistent T cell activation with each experiment. To this end we
tested various combinations of soluble and plate-bound αCD3/αCD28 antibodies
at different concentrations. Eventually, we developed a conditional culture system
that was based upon the final number of cells in each well (Table 3.1).
Table 3.1: Conditional T Cell Activation Algorithm for Co-cultures.
Total Cell # / Well
(aMDSCs + T Cells)

[αCD3]
(Plate-bound)

[αCD28]
(Plate-bound)

5000 – 10000

3 μg/mL

3 μg/mL

> 10000

1 μg/mL

3 μg/mL

Once we had a system in place to consistently induce T cell proliferation,
we turned to the problem of measuring the potential suppressive activity of the
adipose-derived cells. As the pilot experiments had demonstrated, cytometrybased methods were theoretically possible. In practice however, this turned out to
be tedious and extremely time-consuming. More importantly CFSE-dilution was
not nearly as sensitive of a detection method when it was scaled down to the level
of 6000 T cells per well. An issue that was further compounded by the fact that
these cells were being co-cultured with adipose SVF, which notoriously autofluoresces in the FITC channel (the same channel used to detect CFSE signal).
This desire to produce consistently reliable and unambiguous results motivated
our search for alternate ways to assess aMDSC-mediated changes in T cell
proliferation.
Eventually we landed on a new form of MTT assay, which preserved cellular
viability by producing a soluble dye instead of an insoluble precipitate. This left us
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the option to further analyze the co-cultures using flow cytometry or even to assess
T cell activity over time as long as the cells were washed and resuspended in fresh
media afterwards. The major advantage of this type of assay however was its
sensitivity, as it could provide an accurate assessment of cell number in cultures
with as few as 5000 cells per well.
Choosing this method did require a few compromises on our part. For
instance, in cytometry-based systems you have the option to stain for cell-specific
markers which allows for the identification of the exact cell populations that are
proliferating. Since the MTT assay format, at its core, is a semi-quantitative,
relative assessment of cell number in each well and is based on their metabolic
activity it is impossible to know what cells are contributing to the differences
between conditions. This meant that we could not assume that absorbance value
differences between the positive controls and the experimental conditions were
solely due to changes in T cell proliferation. However, we determined that the loss
of this specificity was acceptable as the more traditional H 3-thymidine incorporation
method suffers from a similar issue in that all proliferating cells are radio-labeled,
not just T cells.
The MTT assay format we chose was a water-soluble tetrazolium salt
(WST) assay and is based on the activity of cellular dehydrogenases. These
essential enzymes are involved in oxidative phosphorylation and use the potential
energy of electrons to actively transport hydrogen ions into the intermembrane
space of mitochondria. The electrons released during the oxidation reactions are
then transferred to an electron mediator such as ubiquinone. This is the step that
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the WST assay takes advantage of. The reagent is added directly to the co-culture
supernatant and contains its own water-soluble electron mediator. This molecule
scavenges the electrons that typically reduce ubiquinone and transports them
extracellularly where they can be used to convert a tetrazolium salt into formazan,
a water-soluble dye. As cellular dehydrogenase activity increases, more electrons
are released, resulting in an increased production of formazan. Ultimately, this
changes the color of the culture supernatant from light yellow to orange, which is
then quantified by measuring light absorbance at 450nm. The higher the
absorbance value is, the more metabolic activity that is going on in the well, and
the more cells in that particular culture condition.
Even with three successful iterations of this MTT-based assay under our
belts, we were still concerned about the fact that at its core MTT assays rely on
the assumption that all the cells within a given co-culture are metabolizing at a
comparable rate. Since we had improved the reliability of our small-scale T cell
activation protocol, we decided to try the flow cytometry-based proliferation assays
one again in order to verify that the absorbance changes we observed in the MTT
assays did result from a true decrease in T cell proliferation. Cell number titrations
revealed that we were able to reliably measure CFSE dilution with as few as 5000
MACS-enriched T cells. Additionally, these titrations indicated that Day 3 of the
culture would be the optimal time to collect proliferation data as the CFSE dye was
completely diluted and undetectable by Day 4 (Figure 3.1). All in all, three T cell
suppression assays were performed according to these parameters. None of them
however showed that adipose-derived MDSCs (aMDSCs) had any of the
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suppressive activity that was observed in the previous MTT assays (Figure 3.2 a).
After comparing the set-up of the MTT and CESE assays we determined that there
were two major differences that could have resulted in these discrepancies
between the sets of experiments: the kinds of responder cells we used and the
length of time the cells were co-cultured.
The original MTT assays used splenocytes while MACS-enriched T cells
were used for the CFSE set. Given the diverse array of effector mechanisms at
their disposal, it was possible that MDSCs were promoting M2 polarization in
splenic macrophages which were then responsible for the observed reduction in T
cell proliferation. To test for this, we compared aMDSC-mediated suppression
between MACS-enriched T cells and splenocytes. Once again, we did not see any
immunomodulatory activity in the co-cultures with MACS-enriched T cells.
Surprisingly, suppressive activity was absent from the splenocyte co-cultures as
well (Figure 3.2 b). This implicated the time that these cells spent in co-culture as
the source of these discrepancies.
The CFSE-based proliferation assays as well as the assay comparing
splenocytes and purified T cells were all analyzed on culture Day 3, while the cocultures in the original set of MTT experiments had been allowed to run through
Day 5. To this end, two sets of MDSC co-cultures were set up simultaneously with
proliferation being assessed on either Day 3 or 5. We had to return to the MTT
format for those experiments as CFSE would be completely diluted by Day 5
(Figure 3.2 c). Using these parameters, we observed a striking difference between
days 3 and 5 in terms of MDSC-mediated suppression of T cell proliferation. As
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with previous experiments there was little to no suppressive activity on culture Day
3 regardless of whether MDSCs were co-cultured with splenocytes or MACSenriched T cells. By Day 5 however, the PI in MDSC co-cultures was significantly
less than one indicating that suppression had occurred (Figure 3.2 c). As further
verification of these results, T cells were counted in each well after absorbance
measurements were taken. Here we found that MDSC co-cultures on Day 5 had
significantly fewer T cells than the positive controls, while there wasn't a difference
between the two culture conditions on Day 3. Besides providing additional
optimization parameters for these suppression assays, these troubleshooting
experiments gave us valuable insight into aMDSC biology. First, whatever effector
mechanism aMDSCs are using does not prevent the initial activation and
subsequent proliferation of naïve T cells. Instead it appears to stop proliferation
over time, once it has already started. Second, aMDSC-mediated immune
modulation can directly affect T cell proliferation without the need for an
intermediary cell type such as M2 macrophages (Figure 3.2 d).
As the MDSC-mediated suppression could only be detected after 5 days,
we were once again faced with the problem of non-specificity. The MTT format is
more often used to determine the cytotoxicity of a specific treatment or drug.
Traditionally, these cell viability assays use a single cell line making it easy to
assume that changes are due to the experimental conditions themselves and not
different cell types behaving differently. However, for our suppression assays,
there would be two (aMDSCs and MACS-enriched T cells) or more (in the case of
splenocytes) different cell types in each co-culture. This heterogeneity meant that
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the results could not be taken at face value, as the metabolic activity of our effector
cells could inadvertently be influenced by the presence of activated T cells. To
account for this, we developed a secondary method to verify the final number of T
cells in each culture condition. On day 5, following the final MTT absorbance
measurement, cells were washed and stained with CD4 and CD8 antibodies. Then
the entirety of each individual well was collected at the cytometer in order to
calculate the final number of T cells in each co-culture. Finally, we correlated the
absorbance values from the MTT assay with the absolute number of CD4 + T cell
numbers in each well (Figure 4.4 e). This revealed that there was a strong
correlation between these two values (R = 0.9978), confirming that this assay could
be used to reliably measure both T cell proliferation and the suppressive potential
of adipose-derived MDSCs in a heterogeneous mixture of cells.
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Figure 3.1: CFSE can be used to measure the proliferation of as few as 2500
MACS-enriched T cells. (a) Schematic of CFSE titration experimental design. (b)
Histograms showing CFSE dilution profiles in αCD3/αCD28-stimulated CD4 + T
cells after 3, 4, or 5 days.
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Figure 3.2: MDSCs suppress αCD3/αCD28-stimulated proliferation of
splenocytes and MACS-enriched T cells. (a) Naïve, CFSE-stained, MACSenriched T cells were activated with plate-bound αCD3/αCD28 and co-cultured
with aMDSCs. After 3 days CD4+ T cell proliferation was assessed by measuring
CFSE dilution with flow cytometry. Data is pooled from three independent
experiments where each co-culture was performed in triplicate. (b) Naïve
splenocytes or MACS-enriched T cells were activated with plate-bound
αCD3/αCD28 and co-cultured with aMDSCs. After 3 days proliferation was
assessed via MTT assay. Data derived from one experiment where each coculture condition was performed in triplicate. (c) αCD3/αCD28-stimulated
splenocytes were co-cultured aMDSCs for three or five days. Proliferation was
assessed at each time point via MTT assay. Data derived from one experiment
where each co-culture condition was performed in triplicate. (d) Naïve splenocytes
or MACS-enriched T cells were activated with plate-bound αCD3/αCD28 and cocultured with aMDSCs. Proliferation was assessed after five days via MTT assay.
Data pooled from two independent experiments where each condition was
performed in triplicate.

57

Accommodations for the Unique Nature of Adipose Stromal Cells
Flow Cytometry Gating Strategies
As this was the first time that anyone had specifically looked at the impact
of αGr1 depletion on healthy adipose, we were uncertain as to what kinds of
changes we could expect in terms of immune cell dynamics. We hypothesized that
MDSC depletion in vivo would increase signs of overt inflammation in the tissue.
However, we were unsure as to the exact ways in which this might manifest. We
developed multi-color staining panels for flow cytometry to identify and
characterize a broad range of cell types, classically associated with obesity-related
AT inflammation.
Some of the earliest charges that occur at the cellular level in obesity take
place in the macrophage and T cell compartments [141, 142], so we chose to
analyze each sample with two distinct staining panels that targeted some of the
key phenotypic features of each of these cell types. The MDSC/Macrophage panel
included some of the classic markers associated with the "M2" to "M1" phenotypic
switch that occurs in the early stages of obesity [21, 29] (Figure 3.3 a).
Occasionally, due to a shortage of the CD301 or Ly6G antibodies, an alternative
gating strategy was used to define adipose tissue macrophages (Figure 3.3 b) and
MDSCs (Figure 3.4 a). There was no difference between these two strategies in
the final number of MDSCs found within the tissue (Figure 3.4 b). As for the panel
designed to detect changes in T cell dynamics, we included markers indicative of
T cell activation in case MDSC depletion elicited an inflammatory response similar
to what is observed in obesity. This panel also included markers that could be used
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to distinguish between various T cell subsets (i.e. regulatory, effector memory, and
central memory T cells) which are sensitive to changes in the inflammatory state
of AT [39] (Figure 3.5).
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Figure 3.3: SVF Myeloid Cell Gating Strategy (a) Gating strategy used to
characterize MDSCs and adipose tissue-resident macrophages (ATMs) in AT SVF
(b) Alternate ATM gating strategy used when CD301 was not present in staining
panel (c) Cell markers and the fluorophores used to characterize myeloid cell
populations in the spleens and AT SVF of C57Bl/6 mice.
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Figure 3.4: Alternative MDSC Gating Strategy (a) Representative dot plots
depicting the gating strategies used to quantify adipose-resident MDSCs based on
the absence (Upper) or presence (Lower) of Ly6G and CD301 in the staining
panel. The Ly6C vs Ly6G dot plot used in the “Ly6C Hi/Low” gating strategy was
previously gated on the total CD45+ CD11b+ CD301- SVF cells. The CD11b vs
Ly6C dot plot shown in the “Total MDSC” gating strategy was previously gated on
CD45+ SVF cells. (b) Absolute number of MDSCs found in the SVF of untreated
or αGr1-treated mice using either the “Total MDSC” (Blue) or “Ly6C Hi/Low” (Pink)
gating strategies. The numbers shown for the “Hi/Low Gates” gating strategy were
obtained by combining both M-MDSC and PMN-MDSC populations. Bars depict
the mean of 11 untreated or 8 1-week αGr1-treated mice. Error bars depict SEM.
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Figure 3.5: T Cell Phenotype & Activation State Gating Strategy. (a) Gating
strategy used to examine T cell populations in AT SVF. (b) Cell markers and the
fluorophores used to characterize myeloid cell populations in the spleens and AT
SVF of C57Bl/6 mice.
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Adjusting for Adipose Autofluorescence
Once the panels were designed, the cells harvested and the data collected,
we faced an additional challenge on top of our not knowing what specific cell types,
if any, would change as a result of the αGr1 treatment. Adipose tissue is inherently
autofluorescent [143]. This is a problem that plagues any researcher wanting to
use fluorescence-based technology such as flow cytometry or confocal
microscopy to tease apart the inner workings of this tissue. Multiple factors give
adipose tissue and the SVF cells isolated from it their natural fluorescent qualities.
One major factor is the dense extracellular matrix (ECM) that acts as the
scaffolding that holds adipocytes in place and allows the stromal cells to travel
throughout the tissue. A large portion of the ECM is composed of collagen fibers.
The uniform, repetitive structure of this multi-unit protein predisposes it to vibrating
at resonance frequencies [144, 145]. As a result, certain wavelengths of light cause
these subunits to absorb enough energy that an election jumps up one energy
level. As this energy dissipates, the election falls back to its original energy state
consequently emitting a different wavelength of light [144].
The extracellular matrix in adipose tissue is a major contributor to its natural
fluorescence. This dense network of collagen and elastin fibers is an essential
scaffold that holds adipocytes in place and allows stromal cells to travel throughout
the tissue. Collagen fibrils are the primary structural proteins of any ECM and
adipose is no exception [146, 147]. Each fibril is composed of three long α-helical
subunits which twist together to form the final triple helical quaternary structure or
this protein. The amino acid sequences are strikingly regular, exhibiting a fairly
consistent pattern of Glycine–Proline–X, where X can be any amino acid [146].
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The identity of this third residue can influence the fluorescent nature of the final
protein [144]. This feature is mostly observed with the inclusion of any of the
aromatic amino acids: tryptophan, tyrosine, or phenylalanine. Structurally each of
these molecules contains at least one benzene ring. Molecular ring structures,
such as these, are uniquely able to retain their stability upon absorbing light
energy. The absorbed photon excites electrons in the molecule causing them to
jump to a higher energy state, but as this energy dissipates the elections fall back
to their original energy level [148]. This leads to the emission of photons at a lower
wavelength. Most collagen types contain a non-negligible number of tyrosine
residues [146]. Collagen type VI, found in adipose [149], contains both tyrosine
and phenylalanine residues, further enhancing the innate autofluorescence of the
ECM in this tissue.
In addition to aromatic amino acids within individual collagen fibrils, protein
crosslinking can enhance a tissue’s autofluorescent qualities. For instance, a
fluorescent compound known as pyridinoline forms as a byproduct of structural
crosslinking between collagen and elastin fibrils during the formation and
maturation of extracellular matrices in tendons and bones [145].
The final factor contributing to the auto fluorescence of our adipose SVF
cells may actually result from the collagenase digestion itself. A recent study
analyzed how collagenase I digestion altered the structural and fluorescent nature
of collagen I [150]. They found that the innate fluorescence of this protein
increased in a dose dependent manner following exposure to, collagenase I.
Additionally, they determined that this was likely caused by an increase in the
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exposure of tyrosine residues that have otherwise been shielded from direct light
exposure by the triple helical structure of the intact protein.
Since we know that the digestion process only breaks down the collagen
fibers but does not fully dissociate their connections to the cells themselves, it is
very possible that the autofluorescence we observe in our SVF isolates stems, to
some degree, from exposed tyrosine and phenylalanine residues on partially
digested cell-associated collagen.
Along

with

ECM-associated

autofluorescence,

adipose-resident

macrophages also contributed to the spectral interference we encountered in our
flow cytometric analysis of SVF samples. ATM autofluorescence is thought to be
directly related to their functional activities within the tissue. For instance, one
study found that macrophages with upregulated iNOS expression and activity were
more fluorescent in the 488 channel than those expressing lower amounts of this
enzyme [143]. They postulated that this increased fluorescence was likely caused
by an increased concentration of the cofactors required for iNOS activity as 3 out
of these 5 compounds have autofluorescent properties that emit light is the 488
nm range. This same study also found that ATM autofluorescence increased
proportionally with increased lipid uptake by these cells. They ascribed this lipidinduced autofluorescence in ATMs to the high fat diet condition since they
phagocytose the lipids released when overburdened adipocytes pyropoptose. A
more recent study however found that ATMs in healthy mice also actively
participate in lipid uptake and release, potentially acting as intermediaries between
the adipocytes and systemic circulation [25].
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The natural fluorescent qualities of adipose tissue proved to be one of the
most troublesome aspects of our flow cytometry experiments, primarily affecting
our ability to accurate analyze our data by complicating the compensation process.
We sought to reduce these issues as much as possible at every stage of the
experiment. For instance, as we developed our staining panels, we tried to avoid
using FITC or Alexa Fluor 488 conjugated antibodies since this is the major
channel in which AT autofluoresces (Figure 3.6 a). Some of our panels had as
many as 8 colors however, so this was not always possible. In these cases, the
software generated compensation matrices were often thrown off by the inherent
FITC positive aspects of our unstained controls. Additionally, some of the markers
in our more exploratory panels were exclusionary or expressed at such low levels
that using SVF cells for our single-color controls was not feasible. To ensure that
we collected the best data possible and that we were able to accurately analyze
these results we chose to use compensation beads.
As an additional control we used the fluorescence minus one (FMO)
technique to correct for the data spread that occurs when multiple colors are
combined into the same staining panel. This allowed us to identify the true line
between negative and positive cell populations in these multi-parameter
experiments.
Although each of these strategies helped to minimize the impact of
autofluorescence on the data collection portion of each experiment, they were still
only partially effective and the autofluorescent nature of adipose tissue and SVF
cells was still measurable in most of our samples. Our primary means of correcting
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this spectral overlap was by designing our own compensation matrices in the
FlowJo analysis software (Figure 3.6 b). For each set of experiments, I would try
to keep this matrix as consistent as possible between replicates. This was
relatively easy to do as long as the data for each fluorophore was collected at the
same PMT voltages as all the other replicates. Instead of building a new matrix
from scratch or even having designing one based on my single-color compensation
beads in FlowJo itself, I would often use the acquisition defined matrix as my
starting point and adjust the overlap values as needed.
I was able to determine what values required adjustment by looking at the
dot plots of a fully stained sample and an unstained sample. I would then look at
the plot for each fluorophore combination. Primarily I wanted to see that the
displayed populations were distributed in a "natural", round shape as opposed to
forming a diagonal line which is indicative of under compensation. I also adjusted
overly compensated parameters which appeared as diagonal populations that
extended beyond 0 for that fluorophore.
The main concern when making compensation matrices by hand is overly
adjusting the spectral overlap to the point that you inadvertently create false
positive or negative cell populations. In my compensation process I paid particular
attention to these potential artifacts and avoided definitively gating on populations
that drastically shifted intensity with small charges in overlap values. Altogether by
employing these strategies at each stage of the experiment we were successfully
able to produce consistent and reliable data from multi-parametric flow cytometry
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experiments despite the inherent autofluorescence of adipose resident
macrophages and SVF cells in general.
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Figure 3.6: Flow cytometry analysis of SVF requires manually adjusting
spectral overlap values to account for the natural autofluorescence of AT.
(a) Representative histograms comparing FITC or APC fluorescence in full SVF
samples that were either left unstained (Pink) or stained for myeloid cell markers
(Blue) (b) Representative dot plots depicting SVF samples that were either left
unstained (Upper Row) or stained for T cell markers (Lower Row). SVF cells
isolated from the same animal were used for both the unstained and stained
samples. Data shown in the left column uses the compensation matrix calculated
from the DIVA software and single-color stained compensation beads. The righthand column shows the same dot plots after correcting for autofluorescence.

69

CHAPTER 4: BONA FIDE MYELOID-DERIVED
SUPPRESSOR CELLS IN HEALTHY ADIPOSE TISSUE
Previous work in our lab has examined the therapeutic value of the adipose
tissue (AT) stromal/vascular cellular fraction (SVF) in improving vascular function
[85, 151, 152]. In one study the SVF isolate lost many of its beneficial effects when
the CD11b+ cells were depleted [85]. Further characterization of these
therapeutically relevant CD11b+ cells found that approximately 45% of were also
Gr1+. Similar populations of CD11b+ Gr1+ cells have been observed by others in
the AT of healthy, control animals [129, 153], yet no detailed characterization of
these cells has been performed to date. Given the immunomodulatory nature of
the adipose tissue stromal cells in healthy mice we hypothesized that these
CD11b+ Gr1+ cells were an adipose-resident population of immunosuppressive,
myeloid-derived suppressor cells (MDSCs).

There are CD11b+ Ly6CHi/Low Ly6G-/+ CD301- cells in healthy adipose tissue.
In

order

to

determine

if

these

CD11b+

Gr1+

cells

could

immunomodulatory, myeloid-derived suppressor cells (MDSCs), we

be
first

developed a detailed panel of surface markers to characterize the myeloid cell
populations resident in healthy adipose tissue (AT). Ly6C and Ly6G were included
as well as AT-resident macrophage markers F4/80, CD301, and MHC-II to
differentiate neutrophils and polymorphonuclear-MDSCs (PMN-MDSCs) from
adipose tissue macrophages, dendritic cells, and monocytic-MDSCs (M-MDSCs).
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CD11b+ CD301- CD11c- Ly6CHi/Low Ly6G+/- MDSC-like cells made up 0.77 ± 0.07%
of the SVF harvested from healthy AT. 85.73 ± 1.8% of these were Ly6CHi Ly6GM-MDSC-like cells (0.63 ± 0.09% of the total SVF), while Ly6C Low Ly6G+ PMNMDSC-like cells accounted for the remaining 14.28 ± 1.76% of the CD11b + CD301CD11c- cells (0.12 ± 0.03% of the total SVF) (Figure 4.1 a – b). Neither population
of the cells we identified expressed traditional adipose macrophage or dendritic
cell markers such as CD301, F4/80, or CD11c; however, the Ly6C Hi Ly6G- cells
did exhibit heterogeneous expression of MHC-II (Figure 4.1 c).
PMN-MDSCs can be difficult to distinguish phenotypically from CD11b +
Ly6G+ neutrophils. Cells with this surface marker combination only account for
0.15 ± 0.03% of the total SVF (3.72 x 103 ± 0.77 cells / mL AT) with the majority
falling into the CD11b+ Ly6CLow Ly6G+ population (67.3 ± 7.0% of total Ly6G+ cells)
(Figure 4.2). Furthermore, we believe that these Ly6G+ cells are likely to share
more functional characteristics with PMN-MDSCs than with neutrophils since other
groups have shown that there are very few neutrophils in healthy adipose tissue
[154, 155].
Overall, the surface markers expressed by the Ly6C Hi Ly6G- and Ly6CLow
Ly6G+ SVF populations are comparable to those found on tumor-associated MMDSCs and PMN-MDSCs, respectively [102]. Since the Ly6C + Ly6G- cells
represented a majority of the candidate CD11b + CD301- CD11c- population, we
decided to focus our subsequent characterization studies on this subset.
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Figure 4.1: CD11b+ CD301- Ly6CHi/Low Ly6G+/- cells are in adipose tissue from
metabolically healthy mice. (a) Representative zebra plots depicting the gating
strategy used to characterize the myeloid cell populations in adipose tissue from
individual, healthy mice. (b) Quantification of the CD11b+ CD301- populations in
the stromal vascular cell fraction (SVF) isolated from healthy AT. Adipose from 11
mice analyzed individually. Error bars represent SEM. (c) Representative
histograms depicting surface expression of macrophage markers by CD11b +
CD301- Ly6CHi Ly6G- cells (Blue line), Ly6CLow Ly6G+ cells (Pink line), or
Fluorescence-minus one (FMO) controls (dashed line) in healthy AT. Selected
histograms depict median expression within the group of 11 individuals analyzed.
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Figure 4.2: PMN-MDSCs make up the majority of Ly6G+ cells in healthy
adipose tissue. (Left) Overlaid contour plots showing the portion of CD11b+
Ly6G+ cells that are PMN-MDSCs in the SVF of healthy mice. (Right) The
frequency of different cell subsets within the CD11b + Ly6G+ SVF population.
Adipose from 4 mice analyzed individually.
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Adipose-resident CD11b+ Ly6CHi Ly6G- cells express canonical MDSCassociated genes.
Simply expressing surface markers reminiscent of tumor-derived MDSCs is
not sufficient evidence to definitively characterize these adipose-resident cells as
a genuine population of MDSCs. Because we only recovered 9 - 10 x 10 3 MMDSC-like cells per mL of AT with each sort we were forced to limit the number of
genes we could probe for. In the tumor microenvironment MDSCs can be
distinguished from normal monocytes by their co-expression of immunoregulatory
molecules and cytokines such as arginase (Arg1), inducible nitric oxide synthase
(Nos2), VEGF, PGE2, IL-4R, IL-10, and TGFβ [100]. We focused our analysis on
Arg1, Nos2, Il10, and Tgfb1 as these genes are considered “crucial” for MDSC
biology by Bronte et al (2016) [100]. Traditionally, Nos2 and Arg1 expression are
used to distinguish “M1” from “M2” macrophages. In tumors however coexpression of these two enzymes is considered a classic feature of MDSCs.
Further differentiating MDSCs from monocytes is their active transcription of antiinflammatory cytokines such as IL-10 and TGFβ.
To determine if our adipose-derived Ly6CHi Ly6G- cells were actively
transcribing these MDSC-associated genes, we isolated RNA from sorted CD11b +
Ly6CHi Ly6G- SSCLow cells and performed qRT-PCR. Transcriptional analysis of
the sorted, adipose-resident CD11b+ CD301- Ly6CHi Ly6G- cells revealed
abundant transcripts of Arg1, Nos2, and Tgfb1 (Figure 4.3 a). They also expressed
low levels of Il10 (Figure 4.3 a).
Intriguingly we also found that these adipose-resident cells were actively
transcribing Il33 (Figure 4.3 a). This cytokine plays an important role in regulating
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the immunomodulatory phenotypes of several of the key cell types integral to the
homeostatic immune network in healthy AT. The cellular source of IL-33

in

adipose tissue has yet to be identified [31], so finding active transcription of this
cytokine in our sorted cells definitely raises some interesting questions worth future
investigations.
Combined with their surface marker phenotype, the gene expression profile
of these CD11b+ CD301- Ly6CHi Ly6G- cells further highlights their similarity to the
Ly6CHi Ly6G- M-MDSCs found in tumors and at sites of chronic inflammation [100].
Furthermore, when compared with adipose tissue macrophages, the Ly6C Hi Ly6Gcells exhibited a distinct expression pattern for immunomodulatory genes such as
Arg1, Tgfb1, and Il10 (Figure 4.3 b), suggesting that these cells may have a unique
role within the AT immune cell network.
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Figure 4.3: Gene expression in Sorted CD11b + CD301- Ly6CHi Ly6G- cells. (a)
Representative bands from an agarose gel showing active transcription of MDSCassociated genes in FACS-isolated CD11b + Ly6CHi Ly6G- cells. Data is
representative of three independent experiments with AT of 10 mice pooled for
each experiment. Depicted bands are from the same gel where PCR amplification
of each gene was tested in duplicate. Gene amplification confirmed using Tbp as
a housekeeping gene and primer specificity confirmed with non-template controls
(NTC). (b) Heat map depicting relative expression of Arg1, Tgfb1, and Il10 by
FACS-isolated adipose tissue macrophages (ATMs) or CD11b + Ly6CHi Ly6Gcells. Each row represents one independent experiment where AT from 5-10 mice
was pooled and mRNA was collected from the indicated cell types. Tbp was used
as the housekeeping gene for each experiment.

76

CD11b+ Ly6C+ Ly6G- AT cells suppress activated T cell responses.
Given that healthy adipose tissue is constitutively inflamed [13] and contains
a network of tissue-resident immunomodulatory cells similar to what is found in the
tumor microenvironment, we hypothesized that the CD11b + CD301- Ly6CHi Ly6Gadipose cells were bona fide, immune suppressive MDSCs. The “gold standard”
for differentiating MDSCs from monocytes or neutrophils is their ability to suppress
activated T cell proliferation [100]. To test this, CD11b + CD301- Ly6CHi Ly6G- cells
were sorted from the adipose stromal cells of metabolically healthy mice and cocultured at a 1:1 ratio with αCD3/αCD28 activated splenocytes for 5 days. The use
of traditional flow cytometry or radiation-based proliferation assays was not
feasible, as the small number of CD11b+ CD301- Ly6CHi Ly6G- cells obtained from
each sort (~ 9 - 10 x 103 M-MDSC-like cells / mL of AT) made it difficult to reliably
obtain repeatable results with these standard methods. As an alternative, T cell
proliferation in these co-cultures was assessed using a colorimetric MTT assay
(Figure 4.4 a). When co-cultured with the isolated Ly6CHi Ly6G- cells and
stimulated with plate-bound αCD3/αCD28 antibodies, we found that activated
splenocyte proliferation was significantly attenuated relative to stimulated
splenocytes alone (PI: 0.38 ± 0.15) (Figure 4.4 b).
We also co-cultured these adipose-derived cells with MACS-enriched T
cells in order to verify that they were directly affecting T cell proliferation, and not
promoting the immune suppressive functions of another cell type present in the
heterogeneous splenocyte isolate which might, in turn, suppress the T cells. Once
again, we found that co-stimulated T cells did not proliferate to the same extent as
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those cultured on their own when they were co-cultured with sorted CD11b +
CD301- Ly6CHi Ly6G- cells (PI: 0.22 ± 0.04) (Figure 4.4 c–d).
Additionally, we correlated the absorbance values from the MTT assay with
the absolute number of CD4+ T cells in each well, as determined by flow cytometry,
following 5-day co-culture. We found that the positive control cultures had the most
CD4+ T cells as well as the highest absorbance values while wells where
αCD3/αCD28-stimulated T cells were co-cultured with Ly6C Hi Ly6G- cells had both
significantly lower absorbance values and fewer CD4 + T cells, confirming that this
assay can reliably measure T cell proliferation (R2=0.9957) (Figure 4.4 e).
Altogether this suggests that these adipose-resident Ly6CHi Ly6G- cells suppress
activated T cell proliferation.
These CD11b+ CD301- Ly6CHi/Low Ly6G- cells exhibit many of the requisite
characteristics of myeloid-derived suppressor cells that accumulate around tumors
or in chronic inflammatory conditions such as the ability to suppress activated T
cell proliferation and the co-expression of arginase and iNOS. As such, we believe
that they are a novel population of MDSCs resident in healthy adipose tissue.
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Figure 4.4: Sorted CD11b+ CD301- Ly6CHi Ly6G- cells suppress αCD3/αCD28
activated T cell proliferation. (a – b) Naïve splenocytes were cultured by
themselves, activated with plate-bound αCD3/αCD28, or activated and co-cultured
with sorted CD11b+ CD301- Ly6CHi Ly6G- cells. After five days splenocyte
proliferation was assessed via MTT assay. (a) Representative MTT results. Wells
depicting each culture condition were selected from a single experiment. (b)
αCD3/αCD28-stimulated splenocyte proliferation in each co-culture condition was
assessed after five days by measuring absorbance (Abs) at 450nm. Abs values
within each experiment were normalized to create a proliferation index (PI) relative
to the mean Abs of αCD3/αCD28-stimulated splenocytes. Bars represent the mean
PI from five independent experiments where each culture condition was performed
in triplicate. Error bars represent SEM. Splenocyte co-cultures MTT plate (c – d)
Naïve, MACS-enriched T cells were either unstimulated, activated with platebound αCD3/αCD28, or activated and co-cultured with sorted CD11b + CD301Ly6CHi Ly6G- cells. After five days T cell proliferation was assessed via MTT assay.
(c) Representative MTT assay results. Wells depicting each culture condition were
selected from a single experiment. MACS: Magnetic-Activated Cell Separation. (d)
αCD3/αCD28-stimulated T cell proliferation was assessed after five days by
measuring Abs at 450nm. Abs values within each experiment were normalized to
create a PI relative to the mean Abs of αCD3/αCD28-stimulated MACS-enriched
T cells. Bars represent the mean PI from one of two independent experiments
where each culture condition was performed in triplicate and the error bars depict
the SEM among those triplicate wells. Differences between positive control
cultures and co-cultures with CD11b+ CD301- Ly6CHi Ly6G- cells determined using
a Student’s t-test. (e) Correlation plot comparing the absolute number of CD4 + T
cells as assessed by flow cytometry and the absorbance at 450nm in each well
after being co-cultured for five days. Each marker represents one well from one
experiment where each condition was performed in triplicate. R 2 value derived
from linear regression. Unstim.: Unstimulated T cells.
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Potential aMDSC Suppression Mechanisms
Given the similarities between the tumor and healthy adipose tissue
microenvironments we wanted to determine if adipose-resident MDSCs (aMDSCs)
employed immune modulation techniques similar to those of tumor-derived
MDSCs, such as sequestering essential nutrients, inducing T cell apoptosis, or
producing

anti-inflammatory

cytokines.

As

we

were

developing

our

proliferation/suppression assay protocols, we performed some pilot experiments
using CFSE-stained splenocytes. Much to our chagrin, we often found no
measurable differences in CFSE dilution between the positive controls and our
aMDSC co-cultures (Figure 4.5 a), suggesting that these cells were not
immunosuppressive. However, when we counted the total number of T cells in
each well, we found that there was a greater number of CD4+ T cells in co-cultured
conditions (8.74x103 ± 0.82 cells/well) after 5 days, than in the unstimulated
controls (4.69x103 ± 0.13 cells/well) suggesting that aMDSCs did not prevent the
initial activation and proliferation of naïve splenocytes. However, the aMDSCcontaining co-cultures did have fewer CD4+ T cells on day 5 than the
αCD3/αCD28-activated splenocyte, positive control cultures (25.66x10 3 ± 4.97
cells/well) (Figure 4.5 b).
These seemingly contradictory suppression results were eventually
reconciled through the use of the MTT assay format. Even though CFSE dilution
proved to be an unsuitable means of measuring aMDSC-mediated immune
suppression, these early experiments did provide some helpful data concerning
the immunomodulatory mechanism of these cells. T cells co-cultured with sorted
aMDSCs were clearly proliferating, as indicated by the observed CFSE dilution
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however, it appeared as if they did not proliferate to the same extent as those
activated and cultured alone, suggesting that aMDSCs were preventing their
continued proliferation but not their initial activation. This pattern was consistent
with two forms of MDSC immune modulation: 1) MDSCs directly induced apoptosis
in activated T cells or 2) promoted T cell senescence or exhaustion. In the following
section I briefly summarize some of the experiments we performed to explore this
question and discuss some of the potential insights that they offer into how
aMDSCs modulate proliferative T cell responses.
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Figure 4.5: Compared to controls, co-culture with aMDSCs reduces the
overall number of T cells, without impeding their initial activation. (a) CFSE
dilution profile in αCD3/αCD28-stimulated CD4 + splenocytes following 5-day
culture alone (Blue) or with CD11b + CD301- Ly6CHi Ly6G- cells (Pink). Histograms
normalized to mode. (b) % CD4+ T cells in each co-culture condition as calculated
by FlowJo Proliferation algorithm. (c) CFSE dilution in αCD3/αCD28-stimulated
CD4+ splenocytes following 5-day culture alone (Blue) or with CD11b + CD301Ly6CHi Ly6G- cells (Pink). Histograms displaying raw cell numbers in each division
peak. (d) The absolute number of CD4+ T cells in each well after splenocytes were
cultured alone or stimulated with plate-bound αCD3/αCD28 and cultured with or
without sorted CD11b+ CD301- Ly6CHi Ly6G- cells for five days. Bars represent the
mean number of cells in each well from one of four independent experiments
where each culture condition was performed in triplicate and the error bars depict
the SEM among those triplicate wells.
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Apoptosis Induction: aMDSCs do not induce apoptosis in αCD3/αCD28
activated splenocytes and T cells.
First, we investigated aMDSC-mediated cell death using our co-culture
system, as an increased rate of T cell apoptosis in aMDSC co-cultures could
explain the significantly reduced number of CD4+ T cells we observed on day 5.
As before, we set up co-cultures of αCD3/αCD28 activated splenocytes with sorted
aMDSCs. After 5 days we assessed proliferation via MTT assay. We then stained
the cells in each well with CD4, CD8, Annexin V, and 7-AAD to quantify the number
of live, apoptotic, or necrotic T cells in each culture condition via flow cytometry.
We found that 67.3 ± 6.9% of CD4+ T cells were in the early or late stages of
apoptosis, 23.6 ± 3.3% were still viable, and 9.1 ± 3.6% were necrotic in the
positive controls (Figure 4.6). Intriguingly, co-culture with adipose-derived MDSCs
did not alter this distribution, with 68.3 ± 8.3% of the CD4 + T cells in some stage of
apoptosis, 23.0 ± 4.8% viable, and only 8.7 ± 3.5% necrotic CD4 + T cells
respectively (Figure 4.6). This suggests that the aMDSCs were not promoting
apoptosis in the activated T cells.
Since the rate of apoptosis was the same between aMDSC co-cultures and
our positive controls co-culture with aMDSCs we hypothesized that these cells
were using a more indirect method of suppression and began to pursue other
MDSC-associated immunomodulatory techniques that could account for the
delayed onset suppression we were seeing. To this end, we focused our
subsequent investigations on the nutrient deprivation, cytokine production, and
oxidative stress mechanisms discussed in the Introduction.
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Figure 4.6: aMDSCs modulate T cell proliferation without inducing apoptosis.
Naïve splenocytes were cultured by themselves, activated with plate-bound
αCD3/αCD28, or activated and co-cultured with sorted aMDSCs. After five days
splenocyte proliferation was assessed via MTT assay. (Upper) Representative dot
plots depicting live, early apoptotic, late apoptotic, or necrotic CD4 + T cell subsets
following 5-day culture of αCD3/αCD28-stimulated splenocytes alone (Left) or cocultured with aMDSCs (Right). (Lower) The proportion of live, apoptotic, or
necrotic CD4+ T cell subsets following 5-day culture of αCD3/αCD28-stimulated
splenocytes alone (Blue) or co-cultured with sorted aMDSCs (Pink). Bars depict
the mean percentage of CD4+ T cells that each subset makes up within that culture
condition from two independent experiments where each co-culture was
performed in triplicate, then combined for Annexin V and 7-AAD staining and
analysis.
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Arginine Sequestration: aMDSC-mediated immune suppression is not
dependent upon arginase activity.
A common immunosuppressive mechanism used by MDSCs is arginine
sequestration. Activated T cells require this essential amino acid to proliferate, but
do not have the cellular machinery to synthesize it themselves, relying solely on
they are able to import from their surroundings. Tumor-associated MDSCs
interfere with this process by upregulating their expression of the argininemetabolizing enzymes arginase and iNOS, drastically reducing the bioavailability
of this amino acid within the tumor microenvironment, arresting any further T cell
proliferation [107].
We first examined the importance of arginase activity to aMDSC-mediated
immune suppression. As before, we set up in vitro co-cultures of αCD3/αCD28
activated splenocytes with either the total SVF isolate, aMDSC-depleted
(ΔaMDSC) SVF, or FACS-isolated aMDSCs. To assess the role of arginase, one
set of these co-cultures were resuspended in our normal culture media while we
used media supplemented with the arginase inhibitor nor-NOHA (200μM) to
resuspend the other set. After 5 days we found that blocking arginase activity did
not affect the proliferative capacity of αCD3/αCD28 activated splenocytes
(Absorbance of 1.38 ± 0.03 vs 1.32 ± 0.02 at 450nm) (Figure 4.7). Additionally, it
did not impair the immunomodulatory activity of aMDSCs, as the extent to which
they suppressed splenocyte proliferation was relatively unchanged by the arginase
blockade (Untreated vs nor-NOHA PI: 0.85 ± 0.03 vs 0.73 ± 0.03) (Figure 4.7).
Indeed, save for a slight trend towards enhanced suppression in nor-NOHA treated
ΔaMDSC SVF (Untreated vs nor-NOHA PI: 0.89 ± 0.07 vs 0.76 ± 0.01) and
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aMDSC co-cultures, there was no clear difference between the untreated and norNOHA-treated wells for any of the co-culture conditions (Untreated vs nor-NOHA
PI: 1.2 ± 0.4 vs 1.1 ± 0.08) in terms of T cell proliferation (Figure 4.7), suggesting
that the immunosuppressive abilities of aMDSCs, and of SVF cells in general, are
likely not mediated by arginine sequestration.
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Figure 4.7: aMDSCs do not rely on arginase-mediated nutrient deprivation to
suppress T cell proliferation. Naïve splenocytes were cultured by themselves,
activated with plate-bound αCD3/αCD28, or activated and co-cultured with various
SVF subsets (Blue). nor-NOHA was added to some of the co-cultures to block
arginase activity (Pink). After five days splenocyte proliferation was assessed via
MTT assay. P.I. of untreated wells calculated relative to untreated αCD3/αCD28stimulated splenocytes and P.I. of nor-NOHA co-cultures calculated relative to
αCD3/αCD28-stimulated splenocytes cultured in media supplemented with norNOHA. Bars represent the mean P.I. in each well from one of four independent
experiments where each culture condition was performed in triplicate and the error
bars depict the SEM among those triplicate wells.
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Immunosuppressive Cytokines: aMDSC cytokine production was below
detection levels in vitro.
We next analyzed the supernatants from these co-cultures using ELISAs to
look for immunomodulatory cytokines that aMDSCs could be using to slow and
eventually halt T cell proliferation altogether [100]. Specifically, we focused on IL10 and TGFβ as we found that aMDSCs were actively transcribing both cytokines
in our characterization studies. In supernatants from one experiment we found, as
one might expect, that IL-10 concentrations were higher in co-cultures with SVF
(3.68 ± 0.44 pg/mL), ΔaMDSC SVF (2.01 ± 0.98 pg/mL), and sorted aMDSCs (1.96
± 0.42 pg/mL) than αCD3/αCD28 activated splenocytes alone (< 0.00 pg/mL)
(Figure 4.8 a). However, these concentrations were at or below the assay’s 5
pg/mL limit of detection. Using supernatants collected from whole SVF co-cultures
containing 6 – 7-fold more cells per well, we found a strong correlation between
the supernatant concentration of IL-10 on culture day 2 and the number of SVF
cells used to begin with (Figure 4.8 b). As such, we were unable to use to measure
IL-10 protein levels in the supernatants collected from our subsequent aMDSC coculture assays.
Fortunately, we were able to detect ample levels of TGFβ in these
supernatants, finding it in every co-culture condition. This suggests including both
that several different cell types are producing TGFβ in the SVF.
Intriguingly there was a marked increase in the concentration of TGFβ when
arginase activity was blocked with nor-NOHA. This was one of the most consistent
trends we observed across the supernatants we tested and was the most
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pronounced in the co-cultures with activated splenocytes and isolated aMDSCs
(113.24 ± 8.6 pg/mL vs 173.6 ± 14.0 pg/mL) (Figure 4.9 a).
When we examined TGFβ concentrations in relation to the MTT proliferation
results from the respective co-culture, we found a significant positive correlation
(Pearson Coefficient = 0.7753). Surprisingly, it appeared as if T cell proliferation
was at its peak in co-cultures with higher levels of TGFβ (Figure 4.9b, blue and
pink markers). The implications of these findings are somewhat muddied however
when you consider that whole splenocytes were used as the responding population
inn these arginase blockade assays. Like the SVF, splenocytes are a
heterogeneous mix of cells, which, in addition to T cells, contain various types of
macrophages, dendritic cells, and B cells [156], any of whose function can be
affected by interacting with MDSCs [89, 102, 107, 114]. It’s possible that our
aMDSCs are preventing TGFβ production in one or more of these splenic cells,
causing the drop in TGFβ levels in the aMDSC and ΔaMDSC SVF co-cultures
compared to our positive controls. Blocking arginase activity could partially restore
the splenocytes’ ability to produce this cytokine, explaining the increase we see in
the nor-NOHA treated co-cultures.
If we focus on just aMDSC co-cultures (Figure 4.9 b, orange markers), we
see that, contrary to the overall trend, suppression increases (P.I. values
decrease) as TGFβ levels rise. MDSCs are a very plastic cell type, capable of
quickly adapting to shifts in their microenvironment. Therefore, it is possible that
the aMDSCs in our co-cultures upregulated their production of TGFβ in response
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to the arginase blockade, allowing them to continue to suppress activated T cell
proliferation.
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Figure 4.8: IL-10 concentrations were below detection in aMDSC co-cultures
due to small number of cells in each well. Naïve splenocytes were cultured by
themselves, activated with plate-bound αCD3/αCD28, or activated and co-cultured
with various SVF subsets. Supernatants were collected from each well after two
days and stored at -80° C for later analysis. (a) Mean IL-10 concentrations as
determined by ELISA. Data derived from the supernatants of one suppression
assay where each condition was performed in triplicate. The error bars depict the
SEM among those triplicate wells. (b) Correlation plot of IL-10 concentrations in
Full SVF co-cultures vs the number of SVF cells plated in each well on day 0. Data
derived from the supernatants of three independent experiments where SVF was
co-cultured with αCD3/αCD28-stimulated splenocytes. Each marker represents
one well. R2 value derived from linear regression. Spln*: αCD3/αCD28-stimulated
splenocytes. P value obtained using Pearson coefficient.
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Figure 4.9: aMDSCs may modulate immune cell activity via TGFβ production.
Naïve splenocytes were cultured by themselves, activated with plate-bound
αCD3/αCD28, or activated and co-cultured with various SVF subsets.
Supernatants were collected from each well after two days and stored at -80° C
for later analysis. (a) Mean concentration of TGFβ as determined by ELISA. Bars
represent the mean protein concentration from of three independent suppression
assays where each culture condition was performed in triplicate and error bars
depict the SEM among those triplicate wells. (b) Correlation plot of proliferation
index vs TGFβ concentration. Each co-culture condition is represented by a
different color. Circles denote wells where cells were cultured in normal media and
X’s represent wells where the media was supplemented with nor-NOHA. R 2 value
derived from linear regression. P value obtained using Pearson coefficient.
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Conclusions
According to the nomenclature standards recommended by Bronte et al
(2016) (ref. 22), a population of cells must fulfill three key requirements in order to
be classified as MDSCs. First, the myeloid cell population must increase in
numbers in a pathological setting as compared to healthy conditions. Second,
these cells should possess a characteristic combination of phenotypic markers,
which includes surface protein, biochemical, and molecular markers. Finally, and
most importantly, they need to be able to suppress inflammatory immune
responses. Our adipose-derived cells are CD11b+ CD301- CD11c- Ly6CHi/Low
Ly6G+/-, do not express macrophage markers such as F4/80 and CD301, express
canonical MDSC-associated genes, significantly attenuate activated T cell
proliferation, and are known to accumulate in the adipose tissue in obesity [129].
Taking all of this into account we conclude that these cells represent a bona fide
population of tissue resident MDSCs within the AT of lean individuals (aMDSCs).
As for the effector mechanisms behind the immunomodulatory nature of
these aMDSCs, we can only speculate. Based on our in vitro data, we know that
aMDSCs abrogate T cell proliferation without preventing their initial activation and
proliferation. They also do not promote apoptosis in these proliferating T cells. This
is consistent with other reports documenting their ability to induce senescence in
activated T cells or regulate their proliferation using methods such as nutrient
sequestration, cytokine production, and nitrosylation [102, 157]. We performed
cursory investigations into each but were unable to definitively identify any one of
them as the primary suppressive method. We believe that, similar to what others
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have shown, these adipose-resident MDSCs most likely employ a combination of
techniques in order to stem T cell proliferation [102].
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CHAPTER 5: MYELOID DERIVED SUPPRESSOR CELLS
REGULATE T CELL NUMBERS & ADIPOSE MACROPHAGE
POLARIZATION IN HEALTHY ADIPOSE TISSUE
Once we determined that these cells were bona fide MDSCs, we
immediately were curious as to what role they were playing in healthy adipose
tissue, particularly since these cells are typically not found in homeostatic immune
states. Ideally, to investigate this we would specifically delete MDSCs from the AT
in vivo and monitor any downstream effects. Unfortunately, the heterogeneous
nature of MDSCs makes it very difficult to develop either an inducible deletion or
transgenic knockout model. To date the best method available to remove MDSCs
in vivo is through the periodic administration of the αGr1 antibody. This monoclonal
antibody successfully removes all Ly6G positive and a portion of the Ly6C positive
cells from circulation no matter whether it is delivered intraperitoneally,
subcutaneously, or intravascularly. We chose to specifically look for changes to
the T cell and adipose resident macrophage populations as the phenotypes and
functions of their tumor-associated counterparts are greatly influenced by MDSCs
[98, 158, 159].

Gr-1 Model of MDSC Depletion
Since I was ultimately interested in how adipose-resident MDSCs
(aMDSCs) fit into the established immune cell network of healthy tissue, I needed

96

to develop a way to see how the tissue was affected when these cells were taken
away. Currently, there is no MDSC-specific knock-out mouse model, but there is a
well-established, antibody-mediated model for in vivo MDSC depletion, which
utilizes the RB6-8C5 clone of the αGr1 antibody. Historically, this model was first
used as a means to investigate neutrophil function in vivo [160, 161] but has since
been adopted by MDSC researchers as a method to study their impact in various
pathological settings [130, 162-165]. In addition to MDSCs and neutrophils, the
Gr1 protein is also expressed by subsets of monocytes [162], dendritic cells [166],
and even CD8+ T cells [167], all of which are susceptible to αGr1-mediated
depletion. To further complicate matters, the actual depletion efficiency of this
model varies between different tissue types [168, 169], with additional questions
even having been raised regarding the standard methods used to verify successful
depletion [168, 170].
With no other effective method for MDSC depletion commercially available
we decided to go ahead with this model as it would allow us to compare the data
from our experiments with the plethora of data from previously published studies.
Additionally, we hypothesized that any effects we observed following the αGr1
treatment would have directly resulted from the loss of aMDSCs in this tissue and
not from the depletion of these other cells [154, 171, 172], since we would be using
adipose from healthy, non-obese mice for the initial phase of our study and healthy
adipose contains very few neutrophils or CD8+ T cells (Figure 5.1).
Moreover, where we could, we tried to minimize and control for the influence
of this model’s inherent "messiness”. For instance, the RB6-8C5 Gr1 antibody
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clone, used for depletion sterically hinders the binding of most Ly6G and Gr1
antibodies available commercially, which means that neither of these markers can
be used in conjunction with flow cytometry or fluorescent microscopy to validate
successful MDSC depletion. As such, we made sure to take this into account when
we designed the flow cytometry staining panels for the depletion experiments.
As mentioned above, there is evidence that this antibody is not efficient at
removing MDSCs from all tissues [169]. To determine whether this model would
remove aMDSCs from visceral adipose depots, we i.p. injected 4 mice (2 males
and 2 females) with 200μg of the αGr1 antibody every 3-4 days for two weeks. The
adipose tissue from these mice was pooled for analysis while their spleens were
analyzed individually to verify successful MDSC depletion. Initially it appeared as
if the antibody had not penetrated into the fat pads of these mice as there was no
real difference in the proportion of aMDSCs in αGr1-treated and untreated SVF.
However, individual analysis of splenocytes from each of these mice revealed that
the depletion had only been effective in two out of the four animals, potentially
explaining the results of our SVF analysis (Figure 5.2). There were two main
differences between the group of mice where the treatment worked and those mice
where it didn’t. The primary factor delineating the two groups was sex; the αGr1
treatment had successfully removed Ly6C+ Ly6G- and Ly6C+ Ly6G+ cells from the
spleens of the female mice, while these two populations were still present in the
male spleens. In addition to sex, the female mice weighed significantly less than
the males, implicating weight as another potential factor involved in determining
whether or not the antibody treatment would be effective. Since sexually dimorphic
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differences in antibody-mediated depletion had not been described in the literature
we concluded that weight was more likely to be the determining factor behind the
variations in our treatment efficacy.
With no other MDSC depletion model available we decided to address these
issues on several fronts. First, we changed the dosing and administration protocols
to account for weight differences between animals, as well as differences is the
size and location of the visceral fat pads. We exchanged the standard
200μg/mouse dose for one that was based on the weight of each mouse (15μg/g).
In this way we could account for size difference between individuals.
Additionally,

we

altered

our

administration

route,

moving

from

intraperitoneal (i.p.) to subcutaneous (s.c.) injections in order to address concerns
regarding differences in fat pad location and size between males and females. The
SVF cells we harvest in our studies are isolated from the epididymal fat pads in
males and the parametrial fat pads in females. Although these two pet depots
serve physiologically analogous functions, anatomical differences mean that the
fat pads themselves are more superficial in males than those in the females. Their
location puts them directly in the area targeted in i.p. injections. Since we were
interested in the treatment’s impact on specifically this tissue, we wanted to avoid
any potential complications or confounding results that could arise from
accidentally injecting the antibody directly into the fat pad. We found that s.c.
administration was just as effective as i.p. injection and improved the consistency
of the depletion between animals.

99

As a final means of optimization, we decided to improve the “resolution” of
our flow cytometric SVF analyses by modifying our cell isolation protocol. Up until
this point the vast majority of SVF experiments in our lab were performed to
investigate its efficacy as a novel cell-based therapeutic. Since the cellular
composition of the AT immune compartment can be affected by factors such as
age [173] , sex [174], weight, stress level [175, 176], and even vendor, there can
be quite a bit of variation among SVF isolates from one healthy animal to the next.
Using co-housed mice can greatly reduce this variability (Figure 5.3 a), but this
was not always possible for experiments that require a large number of SVF cells.
To avoid potential downstream consequences of this variability on experimental
outcomes, the lab developed a protocol that isolated SVF cells from the adipose
of 4 – 10 mice that was pooled. Each aspect of this isolation protocol had been
rigorously and meticulously optimized to maximize the final cell yield and produce
a consistent, standardized cell isolate. Combining tissues from multiple animals
yielded a homogeneous cell product that reflected the “average” proportion and
distribution of each cell type found in the SVF, effectively normalizing the
composition of the final SVF isolate by erasing the variations observed among
individual mice.
Although ideal for functional assays, the normalizing influence of pooling
tissues from multiple mice was masking some of the more subtle changes that took
place on an individual level as we observed in our pilot depletion experiments
(Figure 5.3 a). If we wanted to capture the subtle changes that may result from
removing such a small population of cells from the AT, we would need to improve
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the sensitivity of our analyses, so I developed a version of our isolation protocol
that could reliably isolate SVF cells from the visceral fat pads of a single mouse.
The new, downsized protocol would allow us to examine MDSC depletion-induced
changes in AT immune cell dynamics that would have otherwise been masked by
the homogenization inherent to working with pooled tissue samples. Two major
modifications to this procedure included using smaller collection vessels and
minimizing excess plasticware. For example, in the pooled isolation process, the
adipose tissue is minced and homogenized in a non-tissue culture treated 100 mm
petri dish. The homogenate is then transferred to a 50mL conical tube for
collagenase digestion. If this is done is a timely fashion, issues such as losing
macrophages to plastic adherence are kept to a minimum. However, for the
individual isolation we would be working with far fewer cells, so we needed to
eliminate as many steps as possible from the process where cells were transferred
from one container to another. For the homogenization step this meant mincing
the whole tissue in the same tube where it would be digested.
In general we tried to keep the actual collagenase digestion process as
consistent with the pooled isolation protocol as possible, using the same volume
of (1 mL / mL AT) and recipe for (2 mg collagenase / mL AT; 1 mg DNase / mL AT;
and 1mL 0.1% BSA in DCF-PBS / mL AT) the digestion buffer. Additionally, we
used the same digestion time of 35 minutes for these individual SVF isolations.
We did find it necessary however to modify the environmental conditions in which
the digestion took place. In a standard SVF isolation, we use a programmable,
climate-controlled rotator (Enviro-Genie; Scientific Industries Inc, Bohemia, NY) to
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control the exact temperature and rotation speed of the tubes during the
collagenase digestion. However, the smaller 5mL tubes used in the individual SVF
isolation protocol did not fit in this machine. As an alternative, we digested the
homogenized adipose samples inside of a cell culture incubator to maintain the
37°C temperature required for maximum enzyme efficacy. This change in digestion
environment ultimately introduced two major differences between the individual
and pooled SVF isolation protocols: CO 2 levels and rotation speed. First, the
Enviro-Genie is not airtight, so pooled tissues are digested at environmental CO 2
levels (0.035%-.1% CO2), while the cell culture incubator maintains CO2 levels at
around 5%. To minimize the potential for any confounding effects of this difference
on the digestion process, the tubes containing the tissue and digestion buffer were
closed and sealed with parafilm in environmental CO2 conditions before being
placed into the incubator. Switching from the Environ-Genie to the incubator
presented an additional challenge when it came to proper agitation of the tissues
during digestion. Previous work in the lab had found that got optimal results from
the collagenase digestions at a rotation speed of 35 rpm. Unfortunately, digesting
the tissues in the incubator created a relatively large disparity in the rotation speed
between the two protocols as the generic blood rotator used to agitate the samples
had a fixed speed of 18 rpm. These two factors did not seem to influence the
efficiency of the collagenase enzyme itself as the tissues from both protocols
appeared to be completely digested after 35 minutes.
Even with these modifications in place, we were able to procure SVF
samples from individual mice that were comparable in composition to what we
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produced with the pooled isolation protocol (Figure 5.3 b). Ultimately, by improving
our SVF isolation methods, optimizing the αGr1 dose for each mouse, and
changing how the antibody was delivered, we were able to successfully deplete
MDSCs from both the spleens and adipose tissue of αGr1-treated mice.
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Figure 5.1: Healthy adipose tissue contains very few of the non-MDSC cells
affected by treatment with αGr1. Frequency of CD11b+ Ly6G+ (Ly6G+) cells and
CD8+ T cells in the stromal vascular cell fraction (SVF) of healthy AT. Each circle
represents one of eleven healthy mice that were analyzed individually.
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Figure 5.2: Pooling adipose tissue for analysis masks differences in
treatment efficacy between individual animals. Healthy, 16 – 20-week old
C57Bl/6 mice (2 males & 2 females) were treated with αGr1 (200μg per mouse)
every 3 – 4 days for 1 week. Tissues were harvested and stained for flow
cytometric analysis. Gonadal fat pads were pooled for analysis (Far Left Column)
while spleens from each mouse were analyzed individually to verify successful
MDSC depletion. Dot plots depict the gating strategy used to characterize MMDSCs in each tissue.
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Figure 5.3: Analyzing AT SVF from individuals reveals cage-dependent
variations in immune cell population distribution. Healthy, 16 – 20-week old
C57Bl/6 mice were treated with αGr1 (15μg/g) every 3 – 4 days for 1 week.
Epididymal fat pads were collected one day after the final antibody injection. (a)
Dot plots comparing myeloid populations in AT SVF from four αGr1-treated mice
raised and housed in two separate cages. Values displayed in each plot are
percentage of CD45+ cells that the specified population represents. (b) The
absolute number of SVF cells obtained (normalized to the volume of adipose tissue
harvested) from either pooled (Blue) or individual (Pink) SVF isolation protocols.
Bars depict the mean of 6 pooled or 19 individual, representative SVF isolations
performed independently. Error bars denote the SEM.
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αGr1 effectively removes cells from spleens & adipose after 1 week of
treatment.
To the best of our knowledge, this finding represents the first time that
immunosuppressive MDSCs have been identified in otherwise healthy adipose
tissue. To better understand the role these adipose-resident MDSCs may play in
metabolically healthy tissue, we employed an antibody-mediated model of in vivo
MDSC depletion. Mice received subcutaneous injections of the αGr1 antibody
(15μg/g) every 3-4 days for one or four weeks. This range of time points allowed
us to assess both the acute and chronic effects of the αGr1 treatment in the AT.
One day after their final dose, the epididymal fat pads were collected from each
mouse and examined individually for any differences in the distribution of the
various resident immune cell populations using flow cytometry. After 1 week,
splenocyte analysis confirmed that the treatment had effectively depleted CD11b +
CD11c- Ly6CHi/Low Ly6G+/- cells systemically, with the number of these cells
dropping from 78.0 ± 9.6 x 104 cells/spleen to 5.4 ± 0.9 x 104 cells/spleen (Figure
5.4 a – b). Following treatment, there was a significant reduction in both subsets
of adipose-resident of MDSCs (aMDSCs), with a 79.4% decrease in the absolute
number of Ly6G- M-MDSCs (15.8 x 103 ± 2.4 cells/mL AT vs 3.3 x 103 ± 1.3
cells/mL AT) and a 95.3% reduction in Ly6G+ PMN-MDSC numbers (3.0 x 103 ±
0.98 cells/mL AT vs 0.14 x 103 ± 0.06 cells/mL AT) (Figure 5.5 a – b). To determine
if the changes we observed in the adipose following the αGr1 treatment were nonspecific effects of the antibody treatment, we treated a subset of our mice with rat
IgG2b isotype antibody (15 μg/g) every 3-4 days for 1 week. There was no
difference in the proportion of CD11b + CD301- Ly6CHi/Low Ly6G+/- cells AT SVF
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cells between the isotype-treated (0.8 ± 0.1%) and untreated (0.77 ± 0.07% of the
total SVF) animals (Figure 5.6).
Unexpectedly, we found that the efficiency of αGr1-mediated MDSC
depletion lessened over time. After 4 weeks of αGr1 treatment, CD11b + CD11cLy6CHi/Low Ly6G+/- cells represented 0.6 ± 0.08% of splenocytes (31.85 ± 7.03
cells/spleen) and 0.31 ± 0.06% of the total SVF isolate (0.95 ± 0.19 cells/mL AT)
(Figure 5.4 b & 5.5 b). Although inconvenient, this resurgence of CD11b +
Ly6CHi/Low Ly6G+/- cells is not unprecedented. A 2016 study by Moses et al [170]
describes a “Ly-6G+ cell rebound phase” after regular treatment (twice weekly) with
the αGr1 antibody for more than 10 days. They found that immature, CD11b +
Ly6G+ accumulated in the spleens and circulation of mice that received twice
weekly αGr1 treatments for more than one week. They attributed this effect to
elevated rates of myelopoiesis caused by increased pressure on the bone marrow
to replenish the αGr1-depleted cell populations. Gene transcription and flow
cytometric characterization of these “rebounded” cells revealed that they likely
served an immunomodulatory function in vivo. Additionally, they refer to, but do
not show, data directly demonstrating their ability to suppress activated T cell
proliferation. For our part, we were unable to perform functional characterization
studies on the CD11b+ Ly6CHi/Low Ly6G+/- cells we found in 4 week αGr1-treated
mice since we could not feasibly isolate a sufficient number of these cells from the
SVF of chronically treated animals to set up viable T cell proliferation/suppression
assays.

However, given their phenotypic similarity to those cells described by

Moses et al, it is likely that the CD11b+ Ly6Hi/Low Ly6G+/- SVF cells we observed
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after 4 weeks αGr1 treatment represents a partial restoration of the
immunomodulatory AT-resident MDSCs.
Since the RB6-8C5 clone of the Gr1 antibody has also been used to deplete
neutrophils [160], we assessed the proportion and absolute number of CD11b +
Ly6G+ cells in healthy adipose tissue before and after the αGr1 treatment. As
stated in the previous chapter, we found that CD11b + Ly6G+ cells only accounted
for about 0.15 ± 0.03% of the total SVF (3.72 x 10 3 ± 0.77 cells / mL AT), with the
majority being Ly6CLow Ly6G+ PMN-MDSCs (Figure 4.2). Following the αGr1
treatment the percentage of CD11b+ Ly6G+ cells in the total SVF dropped to 0.04
± 0.02% (0.99 x 103 ± 0.28 cells / mL AT) (Figure 5.7). Given this relative paucity
of Ly6G+ cells in the adipose tissue of healthy mice, we concluded that any αGr1
treatment-induced responses in the adipose tissue were most likely directly related
to the loss of the tissue-resident MDSCs.
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Figure 5.4: αGr1 antibody treatment efficiently depletes splenic MDSCs.
Healthy, 16 – 20-week old C57Bl/6 mice were treated with αGr1 (15 μg/g) every 3
– 4 days for 1 or 4 weeks. Spleens were collected one day after the final antibody
injection. (a) Representative dot plots of splenocytes from healthy, αGr1-treated or
untreated mice. Circle gates indicate cell populations targeted by the αGr1
antibody. Selected dot plots for each treatment group derived from one animal,
representative of the mean of their respective groups. (b) The frequency (Left) and
absolute number (Right) of splenic MDSCs (Ly6C Hi Ly6G- M-MDSCs + Ly6CLow
Ly6G+ PMN-MDSCs) in untreated (Blue) mice or animals receiving 1- (Pink) or 4weeks of αGr1 treatment (Green) mice. Bars depict the mean of 11 untreated, 8 1week αGr1-treated, and 6 4-week αGr1-treated mice. Differences between αGr1treated and untreated animals determined using a Student’s t-test. *: P < 0.05.
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Figure 5.5: αGr1 antibody treatment efficiently removes MDSCs from
epididymal fat pads. Healthy, 16 – 20-week old C57Bl/6 mice were treated with
αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Epididymal fat pads were
collected one day after the final antibody injection. (a) Representative dot plots of
CD11b+ F4/80- adipose tissue (AT) stromal vascular fraction cells (SVF) from
healthy, αGr1-treated or untreated mice. Circle gates indicate cells targeted by the
αGr1 antibody. Selected dot plots for each treatment group derived from one
animal, representative of the mean of their respective groups. (b) The frequency
(Left) and absolute number (Right) of aMDSCs (M-MDSCs + PMN-MDSCs) in AT
SVF from untreated (Blue) mice or animals receiving 1-week (Pink) or 4-weeks of
αGr1 treatment (Green). Bars depict the mean of 11 untreated, 8 1-week αGr1treated, or 6 4-week αGr1-treated mice. Differences between αGr1-treated and
untreated animals determined using a Student’s t-test. *: P < 0.05.
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Figure 5.6: Generic antibody treatment does not affect the adipose-resident
MDSC population. Healthy, 16 – 20-week old C57Bl/6 mice were treated with
IgG2b antibody (15 μg/g) every 3 – 4 days for 1 week. Epididymal fat pads and
spleens were collected one day after the final antibody injection. (a)
Representative dot plots of CD11b+ F4/80- SVF cells IgG2b-treated mice. Selected
dot plot derived from one animal and is representative of the group’s mean. (b)
The frequency of aMDSCs (M-MDSCs + PMN-MDSCs) in AT SVF from untreated
(Blue) and IgG2b-treated mice (Pink). Bars depict the mean of 15 untreated or 5
IgG2b-treated mice from five independent experiments. Differences between
treated and untreated animals determined using a Student’s t-test. NS: P > 0.05.
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Figure 5.7: Ly6G+ SVF cells are efficiently depleted following treatment with
αGr1 antibody. (a) Dot plots characterizing CD11b+ Ly6G+ cell subsets in
untreated (Upper) and αGr1-treated (Lower) mice. (b) The frequency (Left) and
absolute number (Right) of Ly6G+ cells in the SVF of untreated (Blue) and αGr1treated (Pink) mice. Horizontal bars represent the mean of 8 untreated or 4 αGr1treated animals from two independent experiments. Differences between the
αGr1-treated and untreated animals determined using a Student’s t-test. *: P <
0.05.
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Adiposity increases when MDSCs are removed from adipose tissue.
Although we did not collect extensive metabolic data on our αGr1 treated
animals, we did weigh them after each injection and weighed their fat pads after
tissue harvest. These two measures allowed us to calculate a crude percent
adiposity for each mouse at the end of the experiments. Ultimately, we found that
the αGr1 treatment did not affect the overall weight of the mice, even after 4 weeks
of regular injections (Figure 5.8 a).
Compared to untreated mice, acute αGr1 treatment significantly increased
adiposity; however, this effect disappears in our 4 week treated mice (Figure 5.8
b). Without any more detailed metabolic data it is difficult to draw any clear
conclusions from these findings. Particularly since factors unrelated to our
treatment, such as environmental changes, altered microbiota, or where they came
from (in-house colony vs purchased from a vendor), could influence the animal’s
metabolism and lipid burden. Moreover, there was no change in the number of
SVF cells per milliliter of adipose tissue which indicates that the treatment was not
inducing any overt or drastic changes in the tissue’s overall function at any point
(Figure 5.8 c). Intriguingly, we did find a moderate negative correlation between
the percent adiposity of an individual mouse and the number of aMDSCs found in
their adipose, suggesting that aMDSCs may play a role in lipid uptake by
adipocytes (Figure 5.8 d).

114

Figure 5.8: aMDSC depletion does not affect superficial measures of
metabolic health or the cellularity of adipose tissue. Healthy, 16 – 20-week old
C57Bl/6 mice were treated with αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks.
Epididymal fat pads and spleens were collected one day after the final antibody
injection. (a) Weight, (b) percent adiposity [(fat pad weight / total weight) x 100%],
(c) and the absolute number of SVF cells / mL adipose tissue in untreated (Blue),
1-week (Pink), or 4-week (Green) αGr1-treated mice. (d) Absolute number of
aMDSCs / mL AT vs percent adiposity. Each circle represents an individual mouse
from the indicated treatment group. Pearson Coeff.: Pearson Coefficient (derived
from linear regression. Data pooled from 4 independent experiments.
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Both acute & chronic MDSC depletion increases the number of T cells in
healthy adipose tissue.
In general, the absolute number and proportions of the various AT-resident
immune cell subsets were unaffected by MDSC depletion, with one notable
exception: there was a significant accumulation of T cells in the adipose of αGr-1
treated mice (Figure 5.9 a). CD4+ T cells make up around 0.8 ± 0.07% of the SVF
isolate (1.9 ± 0.14 x 104 cells/mL AT) in healthy, 16 – 20-week old male mice. The
frequency of these cells increased to 1.43 ± 0.3% of the total SVF (3.44 ± 0.6 CD4 +
T cells/mL AT) after only 1 week of the αGr1 treatment, expanding further to 1.85
± 0.05% of the SVF (5.28 ± 0.4 CD4+ T cells/mL AT) after 4 weeks of bi weekly
antibody injections (Figure 5.9 b). Treatment with the IgG2b antibody isotype did
not affect the CD4+ SVF population, confirming that their accumulation was directly
related to the loss of adipose-resident MDSCs and was not an off-target effect of
the antibody treatment itself (Figure 5.10 a – b).
Additionally, there was no change in splenic CD4 + T cell number (5.01 ± 0.6
x 106 CD4+ T cells/spleen vs 5.32 ± 0.5 x106 CD4+ T cells/spleen) or frequency
(9.55 ± 0.5% vs 10.17 ± 0.8%) between 1week-treated and untreated controls,
indicating that the influx of CD4+ T cells was isolated to the adipose tissue at this
early time point (Figure 5.10 c). After 4 weeks of the αGr1 treatment however, the
percentage (17.5 ± 1.5%) and absolute number (9.07 ± 1.4 x 10 6 CD4+ T
cells/spleen) of splenic CD4+ T cells significantly increases, suggesting that
prolonged MDSC depletion may lead to low grade inflammation systemically.
Compared to untreated controls, both short-term and long-term αGr1
treatment significantly reduced the frequency (6.42 ± 0.6% vs 2.9 ± 0.1% vs 2.16
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± .0.2%) and absolute numbers (3.27 ± 0.2 x 10 6 CD8+ T cells/spleen vs 1.51 ± 0.1
x 106 CD8+ T cells/spleen vs 1.13 ± 0.2 x 106 CD8+ T cells/spleen) of splenic CD8+
T cells (Figure 5.10 d). This was likely due to the in vivo T cell-eliminating
properties of the RB6-8C5 clone of the Gr1 antibody [167]. This depleting effect
did not impact the levels of CD8+ cells in the adipose tissue however, as there was
not change in their frequency (0.16 ± 0.04% vs 0.19 ± 0.04% of the SVF) and
number (0.5 ± 0.1 x 104 cells/mL AT vs 0.49 ± 0.04 x 104 cells/mL AT) of these
cells following short-term MDSC depletion (Figure 5.9 c). Moreover, SVF from
mice that had undergone chronic MDSC depletion had significantly more CD8 + T
cells (1.5 ± 0.2% of the SVF & 4.6 ± 0.5 x 104 CD8+ T cells/mL AT) compared to
their untreated and 1 week treated counter parts (Figure 5.9 c). The Gr1-mediated
ablation of splenic CD8+ T cells suggested that their accumulation in the adipose
was more complicated than what we observed with the CD4 + T cells. As such we
were wary of reading too much into what their presence in adipose could imply.

117

Figure 5.9: MDSC depletion in healthy adipose tissue results in increased
numbers of T cells. Healthy, 16 – 20-week old C57Bl/6 mice were treated with
αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Epididymal fat pads and spleens
were collected one day after the final antibody injection. (a) Zebra plots of depicting
T cell populations in AT SVF of untreated and αGr1-treated mice. Selected plots
for each treatment group were derived from one animal and are representative of
their respective group’s mean. (b – c) Frequency (Left) and absolute number
(Right) of CD4+ (b) or CD8+ (c) T cells in the SVF of αGr1-treated and untreated
mice. Data pooled from 4 independent experiments. Bars depict the mean of 11
untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4-week αGr1-treated mice
(Green). Error bars represent SEM. Differences between αGr1-treated and
untreated animals determined using a Student’s t-test. *: P < 0.05 and NS: P >
0.05.
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Figure 5.10: αGr1 treatment has differential effects on splenic T cell
populations. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 15 μg/g
IgG2b (a – b) or αGr1 (c – d) every 3 – 4 days for 1 or 4 weeks. Epididymal fat
pads and spleens were collected one day after the final antibody injection. (a) Dot
plots of T cell characterization in AT of untreated (Left) and IgG2b-treated mice
(Right). Selected plots for each treatment group were derived from one animal and
are representative of their respective group’s mean. (b) Frequency of CD4+ T cells
in adipose SVF. Bars depict the mean of 4 untreated (Blue) or 5 IgG2b-treated
(Pink) from three independent experiments. (c – d) Frequency (Upper) and
absolute number (Lower) of splenic CD4+ (c) or CD8+ (d) T cells in αGr1-treated
and untreated mice. Data pooled from 4 independent experiments. Bars depict the
mean of 11 untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4-week αGr1treated mice (Green). Error bars represent SEM. Differences between treated and
untreated animals determined using a Student’s t-test. *: P < 0.05 and NS: P >
0.05.
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Accumulated T cells are effector memory T cells.
T cell accumulation is often an early indicator of the chronic inflammation
seen in obesity. Specifically, activated CD4+ T cells are one of the first cell types
to infiltrate the tissue during the early stages of this disease. With this in mind, we
chose to focus our subsequent studies on comparing our accumulated CD4 + T
cells to those found in obese animals. Using flow cytometry, we investigated the
phenotype of these cells following acute and chronic MDSC depletion. In
agreement with what others have described, we observed a small population of
CD4+ T cells in the AT of our healthy mice [39, 50]. In contrast however, only a
relatively small percentage of the CD4+ cells were Foxp3+ regulatory T cells (TRegs)
[49, 50] (Figure 5.11 a). This disparity is most likely due to the kinetics of T Reg
accumulation in AT, as their population begins to expand around 15-20 weeks of
age [49, 50]. We chose to use 16-20-week-old mice in the present study as this
age range is the human equivalent of middle adulthood when obesity often begins
to develop, while others typically use mice which are 25-30 weeks old. Thus, the
fewer than expected TReg numbers likely reflects this younger age, as T Reg
populations have not yet begun to expand in the adipose tissue of these healthy
mice.
In untreated mice, 86.4 ± 2.41% of the CD4+ T cell compartment in AT was
composed of Foxp3- CD44+ CD62LLow T effector memory cells (TEM). The
predominance of the TEM phenotype among CD4+ adipose tissue T cells was
unaffected by MDSC depletion at any time point (1-week αGr1: 83.9 ± 1.9% of
CD4+ T cells; 4-week αGr1: 84.8 ± 1.3% of CD4+ T cells) (Figure 5.11 b). However,
acute and chronic MDSC depletion markedly increased the absolute number of
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CD4+ TEM in AT from 1.63 ± 0.1 x 104 TEM/mL AT to 2.91 ± 0.6 x 104 TEM/mL AT
and 4.47 ± 0.3 x 104 TEM/mL AT, respectively, (Figure 5.11 c), indicating that the
accumulation of CD4+ T cells in the AT of αGr1-treated mice was limited to this
effector memory subset.
56.9 ± 4.0% of splenic CD4+ T cells (2.99 ± 0.3 x 106 TEM/spleen) exhibited
a CD44+ CD62L- TEM phenotype. As in the adipose, there was no change in the
proportion of TEM within the total CD4+ T cell population (1-week αGr1: 61.5 ± 8.0%
of splenic CD4+ cells; 4-week αGr1: 67.4 ± 2.0% of splenic CD4+ T cells) in the
spleens of αGr1-treated mice compared to controls (Figure 5.12 a – b). This
suggests that the increased number of CD4+ TEMs in the AT of αGr1-treated
animals results from the systemic depletion of MDSCs.

121

Figure 5.11: Accumulated T cells in adipose following αGr1 treatment are
effector memory T cells. (a) Dot plots depicting the characterization strategy
used for CD4+ T cells in AT SVF. Selected plots in each treatment group were
derived from one animal and are representative of that group’s mean. T CM: Central
Memory T cells. TEM: Effector Memory T cells. (b) Frequency of CD4+ SVF cells
that were CD44+ CD62L- TEM. (c) Absolute number of CD4+ TEM in AT SVF. (b –
c) Data pooled from 4 independent experiments. Bars depict the mean of 11
untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4-week αGr1-treated mice
(Green). Error bars represent SEM. Differences between αGr1-treated and
untreated animals determined using a Student’s t-test. *: P < 0.05 and NS: P >
0.05.
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Figure 5.12: The splenic CD4+ CD44+ CD62L- TEM population is unaffected by
systemic MDSC depletion. (a) Dot plots depicting the CD4+ T cell
characterization strategy in the spleens of untreated (Upper), 1-week αGr1-treated
(Middle), and 4-week αGr1-treated mice (Lower). Selected plots in each treatment
group were derived from one animal and represent the mean within that group. (b)
The frequency of CD4+ splenocytes that were CD44+ CD62L- TEM. Data pooled
from 4 independent experiments. Bars depict the mean of 11 untreated (Blue), 8
1-week αGr1-treated (Pink), or 6 4-week αGr1-treated mice (Green). Error bars
represent SEM. Differences between αGr1-treated and untreated animals
determined using a Student’s t-test. NS: P > 0.05.
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TEMs upregulate expression of markers associated with activation &
proliferation.
Most of our knowledge concerning MDSCs comes from studying their
function within the tumor microenvironment. In this setting αGr1-mediated MDSC
depletion not only increases the number of T cells infiltrating the tumor [177], it
also increases their expression of CD69 compared to T cells from non-depleted
controls [178]. Additionally, CD69 is one of the first markers to be upregulated on
the surface of T cells after they’ve been activated and has also been associated
with T cell retention in a peripheral tissue [179]. Relative to their untreated
counterparts, AT-resident CD4+ TEM rapidly upregulated surface expression of this
marker after only 1 week of the αGr1 treatment (1.65 ± 0.12 vs 1.0 ± 0.04). CD69
levels were slightly lower in our chronically treated mice (1.4 ± 0.12) but remained
significantly elevated compared to adipose tissue TEM isolated from untreated mice
(Figure 5.13 a – b). CD69 expression was unaffected by treatment with the IgG2b
isotype alone (Figure 5.13 c – d).
Next, we analyzed Ki-67 expression in the AT SVF cells of 1-week αGr1treated and untreated mice. Compared to controls (Untreated: 18.05 ± 1.1%;
IgG2b: 19.02 ± 1.2%), the percentage of Ki67 + CD4+ cells in the adipose
significantly increased (25.8 ± 0.95%) following MDSC depletion (Figure 5.14 a –
b). This strongly suggests that these cells are proliferating in situ rather than being
recruited into the tissue from circulation.
To further elucidate the activation state of these CD4 + cells, we evaluated
their transcription levels of classic T cell effector cytokines using qRT-PCR.
CD11b- CD4+ cells, sorted from the SVF of αGr1-treated and untreated mice were
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actively transcribing Tnfa at relatively similar levels (Figure 5.15 a – b), while cells
from αGr1-treated animals showed a trend towards the upregulation of both Ifng
and Il2 transcription compared to untreated controls. This could indicate that the
TEM, which accumulate in AT after αGr1 treatment, may have been activated by
exposure to some constitutively present stimuli within the tissue. However, further
experiments using single cell RNAseq or intracellular cytokine staining are
necessary to demonstrate true changes in the functionality of these T cells. Taken
together it becomes apparent that the adipose-resident MDSCs play a significant
part in modulating the expansion of the CD4+ TEM population in healthy AT.
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Figure 5.13: αGr1 treatment, but not IgG2b treatment, increases CD69
expression on CD4+ TEM in adipose SVF. (a) Representative histogram depicting
CD69 expression on CD44+ CD62L- TEM in the adipose of untreated (Blue line), 1week αGr1-treated (Pink Line), and 4-week αGr1-treated mice (Green Line).
Selected histograms for each treatment group were derived from one animal in
each group and are representative of that group’s mean. The dashed line depicts
the fluorescence-minus one control (FMO) for CD69. (b) The geometric mean
fluorescence intensity (MFI) of CD69 expression on CD44 + CD62L- TEM in the SVF
of either 1-week (Pink) or 4-week (Green) αGr1-treated mice relative to untreated
controls (Blue). Data pooled from 4 independent experiments. Bars depict the
mean of 11 untreated, 8 1-week αGr1-treated, or 6 4-week αGr1-treated mice.
Error bars represent SEM. Differences between αGr1-treated and untreated
animals determined using a Student’s t-test. *: P < 0.05. (c) Representative
histogram of CD69 expression on CD44+ CD62L- TEM in the SVF of either untreated
(Blue Line) or IgG2b-treated (Pink Line). Selected histograms for each group were
derived from one animal and are representative of that group’s mean. The dashed
line represents the fluorescence minus one (FMO) control for CD69. (d) The
geometric mean fluorescence intensity (MFI) of CD69 expression on CD44 +
CD62L- TEM in the SVF of either IgG2b-treated (Pink) or untreated (Blue) mice.
Data pooled from three independent experiments. Bars depict the mean of 4
untreated or 5 IgG2b-treated mice. Error bars represent SEM. Differences between
αGr1-treated and untreated animals determined using a Student’s t-test. NS: P >
0.05.
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Figure 5.14: CD4+ T cells in the adipose increase their expression of Ki-67
following acute MDSC depletion. Healthy, 16 – 20-week old C57Bl/6 mice were
treated with αGr1 (15 μg/g) every 3 – 4 days for 1 week. Epididymal fat pads were
collected one day after the final antibody injection. (a – b) Isolated SVF cells were
stained for Ki67 expression and analyzed using flow cytometry. (a) Representative
dot plots of CD4+ T cells in adipose tissue (AT) stromal vascular fraction cells (SVF)
of untreated (Left) and αGr1-treated mice (Right). Gate depicts Ki-67 expression
by CD4+ SVF cells within each treatment group. Selected plots were derived from
one animal and are representative of their respective group’s mean. (b) Frequency
of CD4+ SVF cells that were Ki-67+. Bars depict the mean of 4 untreated and 4
αGr1-treated mice from 3 independent experiments. Differences between αGr1treated and untreated animals determined using a Student’s t-test. *: P < 0.05.
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Figure 5.15: CD4+ T cells may upregulate IFNγ following MDSC depletion.
mRNA was collected from CD11b - CD4+ SVF cells isolated from 1-week αGr1treated mice. (a) Heatmap of genes expressed by CD11b- CD4+ SVF T cells
isolated from αGr1-treated mice. Differential expression determined relative to
untreated controls. (b) qRT-PCR was used to determine their expression of Ifng
(IFNγ), Tnfa (TNFα), or Il2 (IL-2) relative to CD4+ T cells in the AT of untreated
mice (Dashed Line). ΔCT calculated relative to Tbp transcription. Each circle
represents an independent experiment where cells were sorted from the pooled
SVF of five untreated or five αGr1-treated mice. Differences between treated and
untreated animals determined using a student’s t-test. *: P < 0.05.
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Adipose-resident macrophages develop a “mixed” phenotype following
MDSC depletion.
In addition to inhibiting T cell proliferation, MDSCs can also modulate the
function and phenotype of other cells in order to suppress inflammatory responses
[107]. In the tumor microenvironment, crosstalk with MDSCs promotes the protumor, immunosuppressive nature of tumor-associated macrophages [114]. Since
AT-resident macrophages (ATMs) are an integral component of the AT immune
cell network [20], we investigated whether, similar to the tumor microenvironment,
adipose-resident MDSCs promoted the “M2”-like, suppressive phenotype of
ATMs.
As before, we analyzed the adipose stromal cells from αGr1-treated or
untreated mice using flow cytometry to detect any overall changes in the make-up
of the AT myeloid cell compartment. CD11b + CD301+ MHC-II+ ATMs represented
13.16 ± 0.9% of the total SVF (3.62 ± 0.4 x 105 cells / mL AT) in healthy untreated
mice. Both the proportion (1-week αGr1: 13.81 ± 0.9% of total SVF; 4-week αGr1:
10.67 ± 0.6% of total SVF) and absolute number (1-week αGr1: 3.42 ± 0.4 x 10 5
ATMs/mL AT; 4-week αGr1: 3.35 ± 0.3 x 105 ATMs/mL AT) of these cells were
unaffected by the αGr1 treatment (Figure 5.16 a – b). Similarly, we did not observe
difference in frequency or number of ATMs in the SVF of IgG2b treated controls
(Figure 5.16 c).
Acute MDSC depletion did, however, lead to a marked upregulation of
MHC-II and CD11c on these cells, as indicated by a significant increase in the
relative geometric MFI of these two surface markers compared to ATMs from their
untreated counterparts (MHC-II: 1.0 ± 0.07 vs 2.11 ± 0.31 and CD11c: 1.0 ± 0.02
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vs 1.35 ± 0.02) (Figure 5.17 a – b). Additionally, there was a trending decrease in
the MFI of the "M2”-like marker CD301 on the surface of this same population (1.0
± 0.17 vs 0.55 ± 0.23) (Figure 5.17 a – b). IgG2b treatment had no impact on the
expression of these surface markers relative to untreated controls (MHC-II: 1.0 ±
0.1 vs 1.08 ± 0.09 and CD11c: 1.0 ± 0.04 vs 0.92 ± 0.05) (Figure 5.18 a). Notably,
similar alterations in the expression of these ATM surface markers are hallmarks
of the immune dysregulation that occurs in the early stages of obesity development
[21, 29].
ATM surface marker expression following sustained, 4-week ablation of
MDSCs paints a more nuanced picture of AT immune cell dynamics. We found a
three-fold increase in their expression of MHC-II relative to untreated mice (1.0 ±
0.07 vs 3.24 ± 0.5) (Figure 5.18 b – c), while CD11c expression dropped from
what we observed in 1-week αGr1-treated mice and was no longer different from
the levels in untreated mice (1.0 ± 0.02 vs 0.91 ± 0.07) (Figure 5.18 b – c). The
restoration of CD11c expression concomitant with increasing MHC-II levels add
another layer of nuance to our understanding of immune cell dynamics in adipose
tissue. These results perfectly illustrate the plasticity and adaptability of the
immune cell network in healthy adipose tissue revealing the dynamic changes
ATMs can undergo overtime as work to restore of immune homeostasis in the
tissue. Importantly, the ever-increasing levels of MHC-II on the surface of ATMs
also demonstrates the integral part MDSCs play in healthy adipose as the
remaining AT immune cells seem unable to fully return to their original, pre-αGr1
phenotype. Taken together, this suggests that the adaptability of the immune cell
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compartment in healthy adipose tissue relies upon the crosstalk between these
cells and the loss of any single member weakens the whole network.
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Figure 5.16: αGr1 treatment does not affect the number or proportion of
adipose tissue-resident macrophages. Healthy, 16 – 20-week old C57Bl/6 mice
were treated with 15 μg/g αGr1 (a – b) or IgG2b (c) every 3 – 4 days for 1 or 4
weeks. Epididymal fat were collected one day after the final antibody injection. (a)
Frequency (Left) and absolute number (Right) of CD11b + CD301+ adipose tissueresident macrophages (ATMs) in the total AT SVF. Data pooled from 4
independent experiments. Bars depict the mean of 11 untreated (Blue), 8 1-week
αGr1-treated (Pink), or 6 4-week αGr1-treated mice (Green). Error bars represent
SEM. Differences between αGr1-treated and untreated animals determined using
a Student’s t-test. NS: P > 0.05. (b) Representative density plots of CD11c and
MHC-II expression on CD11b+ CD301+ cells in untreated and αGr1-treated mice.
Selected plots in each treatment group were derived from one animal and
represent the mean within that group. (c) Frequency of ATMs in adipose SVF from
untreated (Blue) or 5 IgG2b-treated (Pink) mice. Data pooled from three
independent experiments with a total of 4 untreated or 5 IgG2b-treated animals.
Error bars represent SEM. Differences between treated and untreated animals
determined using a Student’s t-test. NS: P > 0.05.
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Figure 5.17: ATM surface marker expression is altered by acute MDSC
depletion. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 15 μg/g αGr1
every 3 – 4 days for 1 week. (a) Representative histograms depicting MHC-II,
CD11c, and CD301 surface expression on CD11b + CD301+ SVF cells in untreated
(Blue Line) and 1-week αGr1-treated (Pink Line) mice. The dashed line depicts the
fluorescence-minus one control (FMO) for the indicated surface marker. Each plot
depicts one mouse from each group and is representative of the mean within that
group. (b) Geometric mean fluorescence intensity (MFI) of each surface marker on
CD11b+ CD301+ ATMs in 1-week αGr1-treated mice (Circles) relative to untreated
mice (Dashed Line). Horizontal bars represent the mean of 8 αGr1-treated
animals. Differences between treated and untreated animals determined using a
Student’s t-test. *: P < 0.05.
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Figure 5.18: ATMs differentially respond to acute and chronic MDSC
depletion. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 15 μg/g
IgG2b (a) or αGr1 (b – c) every 3 – 4 days for 1 or 4 weeks. (a) Geometric mean
fluorescence intensity (MFI) of indicated surface markers on CD11b + CD301+
ATMs from untreated (Blue) and IgG2b-treated (Pink) mice. Differences between
treated and untreated animals determined using a Student’s t-test. NS: P > 0.05.
(b) Representative histograms of MHC-II (Left) and CD11c (Right) surface
expression by CD11b+ F4/80+ MHC-II+ ATMs in untreated (Blue Line), 1-week
(Pink Line), and 4-week (Green Line) αGr1-treated mice. The dashed line depicts
the fluorescence-minus one control (FMO) for the indicated surface marker. Each
plot depicts one mouse from each group and is representative of the mean within
that group. (c) MFI of CD11c & MHC-II on CD11b+ F4/80+ MHC-II+ ATMs following
1 or 4 weeks of αGr1 treatment. Data pooled from four independent experiments.
Bars depict the mean of 11 untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4week αGr1-treated mice (Green). Error bars represent SEM. Differences between
αGr1-treated and untreated animals determined using a Student’s t-test. *: P <
0.05.
134

ATM gene expression is unaffected by MDSC depletion.
While intriguing, changes in surface marker expression alone were not
enough to conclude that aMDSCs were controlling the immunomodulatory
functions of the ATMS. To determine if in vivo MDSC depletion led to functional
changes in the AT macrophage population, gene expression analysis using qPCR
was performed on CD11b+ CD301+ MHC-II+ ATMs sorted from the AT SVF of
either αGr1-treated or untreated mice. Our analysis focused on some of the key
pro- and anti-inflammatory cytokines associated with ATMs in health and disease
including TNFα, IL-10, and TGFβ. Although there was a trend towards the
downregulation of Il10 and upregulation of Tnfa in αGr1-treated ATMs relative to
untreated controls, there was no significant difference in the overall transcript
levels of these cytokines between the two groups (Figure 5.19). In obesity, ATMs
exhibiting surface marker changes similar to those we observed also upregulate
Arginase transcription. This was not the case for the ATMs we isolated from
MDSC-depleted mice. Finally, we looked at expression of the transcription factor
PPARγ, which is strongly associated with the immunomodulatory nature of many
AT-resident cells including ATMs [180-182]. Again, ATM transcription of this gene
was unaffected by the loss of MDSCs (Figure 5.19). Taken together, our findings
suggest that the loss of aMDSCs, in vivo, leads to phenotypical but not functional
changes in AT resident macrophages; however, further studies using intracellular
cytokine staining or single cell RNAseq are necessary to definitively determine this.
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Figure 5.19: ATM expression of immunomodulatory genes remains
unchanged following αGr1 treatment. mRNA was collected from the CD11b+
CD301+ MHC-II+ ATMs isolated from 1-week αGr1-treated mice. (a) Heatmap of
genes expressed by CD11b+ CD301+ MHC-II+ ATMs isolated from αGr1-treated
mice. Differential expression determined relative to untreated controls. (b) qRTPCR was used to determine their expression of Il10 (IL-10), Tgfb1 (TGFβ), Tnfa
(TNFα), Pparg (PPARγ), or Arg1 relative to ATMs in the AT of untreated mice
(Dashed Line). ΔCT calculated relative to Tbp transcription. Each circle represents
an independent experiment where cells were sorted from the pooled SVF of five
untreated or five αGr1-treated mice. Differences between treated and untreated
animals determined using a student’s t-test. *: P < 0.05.
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Adipose-resident MDSCs regulate whole adipose homeostasis & immune
cell dynamics.
Since ATMs and CD4+ T cells represent just two players in a large,
heterogeneous network of immune cells, we wondered if aMDSCs could be
interacting with other AT stromal cells in any meaningful way. For these studies
we examined gene transcription in the full SVF isolate to assess how the loss of
MDSCs affected the other non-ATM or T cell components of the AT immune cell
network. Along a similar vein, used explored transcriptional changes in whole
adipose tissue isolated αGr1-treated mice to get an idea of what was occurring on
the whole tissue level to determine if dysregulating this network even slightly had
downstream consequences on the tissue’s health.
We focused on the key cytokines, enzymes, and transcription factors whose
transcript levels are known to fluctuate with the inflammatory state of the tissue.
Surprisingly, we found that, relative to untreated controls, αGr1-treated mice had
increased transcript levels of immune suppressive cytokines. Il10 and Tgfb1 were
significantly upregulated in the SVF and AT, respectively, following MDSC
depletion (Figure 5.20 a – b). Additionally, in the absence of aMDSCs,
transcription of Il33 was also significantly upregulated in both the SVF and whole
AT compared to intact controls (Figure 5.20 a – b). This cytokine is of particular
note since it is heavily involved in regulating the ILC2 – ATM arm of the AT immune
cell network [30, 31, 182]. However, in both MDSC-depleted SVF and AT, relative
expression of Pparg was no different from that of untreated mice, similar to what
we observed with the ATMs.
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In contrast to this apparent increase in the suppressive nature of the AT
microenvironment following MDSC depletion, we observed an overall increase in
Ifng transcript levels in the SVF of αGr1-treated mice, relative to their untreated
counterparts. This is most likely due to the IFNγ-producing CD4 + TEM that
accumulate in AT following MDSC depletion (Figure 5.15 b). Interestingly, this
same transcriptional upregulation is not seen at the whole tissue level (Figure 5.20
b). However, the transcriptional profile in αGr1-treated mice, at the whole tissue
level, did exhibit some subtle changes compared to the untreated mice, which
hinted at the importance of adipose-resident MDSCs in maintaining immune
homeostasis in the tissue. For instance, we observed a significant downregulation
of arginase in MDSC-depleted mice compared to untreated controls (Figure 5.20
b), suggesting that the loss of MDSCs in this tissue triggered a change in the
immune regulatory activity of other non-stromal AT cells, potentially even within
the adipocytes themselves. These transcriptional changes we observed at the
stromal cell and whole tissue level do not necessarily indicate that the absence of
adipose-resident MDSCs has shifted the AT microenvironment towards or away
from a more pro-inflammatory state. However, taken together with the alterations
we found in the size of the CD4+ TEM population size and ATM surface marker
expression, it is clear that there are vital components of a robust, healthy adipose
tissue stromal cell compartment.
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Figure 5.20: Adipose-resident MDSCs regulate whole tissue homeostasis as
well as adipose immune cell dynamics. (a,b) Heatmap of gene expression in
the SVF (a) or whole adipose tissue (b) isolated from αGr1-treated (1 Wk #) or
untreated (Ctrl #) mice. Differential expression determined relative to mean ΔΔC T
of the untreated controls. Each row depicts expression of the specified gene from
an individual animal. Grey boxes indicate outliers excluded from differential
expression analysis. (c,d) Relative expression of specified genes in the SVF (c) or
whole adipose tissue (d) of untreated (Blue) or αGr1-treated (Pink) mice. Bars
represent the mean of 8 individual mice whose tissue and cells were processed
independently. Error bars depict SEM. Significant differences between the two
groups determined using Student’s t-test. *: P < 0.05 and †: P < 0.06.
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Conclusions
We believe that we have demonstrated that adipose-resident MDSCs are
an indispensable member of the immune cell network involved in maintaining AT
homeostasis. In the absence of these cells the AT resident effector memory T cells
begin to proliferate showing signs of increased activation with their upregulation of
CD69. In addition to controlling the size of the adipose tissue T EM population, we
have evidence that MDSCs have a moderate influence over ATM phenotype. In
future work it will be interesting to see whether these surface marker alterations
reflect a larger shift is ATM function as well.
We chose to focus on the macrophages and accumulated CD4 + T cells in
healthy AT, as the phenotypes and functions of their tumor-associated
counterparts are greatly influenced by MDSCs [98, 158, 159]. The increased
number of CD4+ TEMs, along with the altered expression of "M1" and "M2" surface
markers on ATMs could suggest that the tissue microenvironment had become
more "pro-inflammatory" as similar changes in cell phenotype and function are
well-known hallmarks of the immune dysregulation and inflammation characteristic
of obesity [154, 183-185]. However, the functionality of these two cell types, as
assessed by cytokine expression, suggests otherwise. Effector cytokine and
enzyme transcription in both ATMs and CD4+ TEMs was unaffected by a MDSC
depletion.
Additionally, we did not see any conspicuous changes in the inflammatory
status of AT in these mice. This result was not totally unexpected however, given
that we were treating healthy animals that were not challenged in any other fashion
besides the antibody depletion. ATMs and AT TEMs are just two of the many diverse
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types of cells that make-up the immune cell network mitigating inflammation in this
tissue [154, 171, 183]. It is likely that they, along with these remaining members of
the network, actively work to counteract some of the pro-inflammatory effects
caused by MDSC depletion. Indeed, there was a significant transcriptional
upregulation of immunosuppressive molecules such as IL-10, TGFβ, IL-33, and
arginase in the SVF and whole AT of Gr1-treated mice, despite expression levels
of these mediators remaining unchanged in the sorted ATMs and CD4 + TEMs.
We did observe some changes in the tissue, that suggests that these
compensatory responses were not sufficient to re-establish immune homeostasis,
as CD4+ TEM accumulated and Ifng transcription increased. Additionally, we
observed a moderate negative correlation between the number of adiposeresident MDSCs and the adiposity of that individual (Figure 5.8 d), suggesting that
the loss of MDSCs increases adipocyte lipid burden. Given the wide assortment of
suppressive effector mechanisms at their disposal [100], MDSCs may modulate
the function of one or more of the other AT-resident immune cells. The disruption
of these unidentified interactions by αGr1 treatment and the subsequent
downstream effects of these missing components of the cell network may account
for the concomitant pro- and anti-inflammatory responses in the tissue.
Although adipose-resident MDSCs do not appear to be master regulators
of immune homeostasis in the tissue, it is clear that AT immune dynamics are
significantly dysregulated without the AT-resident MDSCs. Their ability to influence
the immune activities of significantly larger cell populations is not unique among
immunomodulatory cell types with as few as 30,000 CD8 + “facilitating cells” reliably
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able to promote the successful engraftment of hematopoietic stem cells in an
allogeneic recipient [186]. Additionally, type 2 innate lymphoid cells make up only
about 1% of the AT SVF cells, yet their depletion has significant negative effects
the composition of the healthy adipose tissue immune cell compartment [30, 31,
187]. We propose that aMDSCs are essential players in the complex immune cell
network in healthy AT, actively preventing the accumulation of CD4 + TEM in this
tissue and, to a lesser extent, contributing to the stability of the “M2”-like nature of
adipose-resident macrophages (ATMs), since their depletion leads to increased
“M1”-like ATM, increased CD11c and MHC-II expression, and reduced CD301
expression.
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CHAPTER 6: DISCUSSION & FUTURE DIRECTIONS
MDSCs as Part of the Adipose Tissue Immune Cell Network
Adipose is a dynamic tissue that relies on a diverse network of stromal (both
immune and non-immune) cells to resolve metabolic and tissue remodeling related
inflammation efficiently. With this project we characterized a novel population of
adipose-resident MDSCs (aMDSCs) and gained some insight as to their place
within the greater immunomodulatory cell network of adipose. Based on the
findings, we propose that aMDSCs are an indispensable part of the AT immune
compartment in healthy AT, actively preventing CD4 + TEM proliferation in this tissue
while also contributing to the stability of the “M2”-like nature of adipose-resident
macrophages (ATMs) (Figure 6.1).
Our findings suggest that, once in the tissue, aMDSCs integrate seamlessly
into the homeostatic immune cell network. For instance, we found that, compared
to untreated controls, ATMs downregulate IL-10 transcription (Figure 5.19) and
upregulate surface expression of CD11c and MHC-II (Figure 5.17), after acute
MDSC depletion. Moreover, we found that aMDSCs are actively transcribing IL-10
(Figure 4.3). This combination of factors is also found in the tumor
microenvironment, where tumor-associated macrophages engage in constant
crosstalk with MDSCs via an IL-10-based positive feedback loop [114]. Given that
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ATMs reduced expression of this cytokine in the absence of aMDSC signaling, it
is likely that they interact in a similarly cooperative fashion.
We also uncovered a novel relationship between aMDSCs and adipose
tissue T cells. When we treated healthy mice with αGr1 we found that the number
of both CD4+ TEM and CD8+ T cells increased in the adipose. These T cells
expressed elevated levels of CD69 on their surface and a greater percentage of
them were Ki67+ compared to untreated controls. Once again this is similar to what
others have demonstrated in the tumor microenvironment regarding MDSC and T
cell dynamics [177, 178].

T Cell Dynamics
Our findings suggest that, in conjunction with other adipose stromal cells,
the presence of aMDSCs in the tissue can further temper proliferative responses
by adipose resident T cells. While this is intriguing in and of itself, it also raises a
key question about what is triggering these responses to begin with. At first glance
the adipose-resident T cell reaction to MDSC depletion seems counterintuitive
given that a foreign antigen or inflammatory stimulus is typically required to incite
proliferation and neither are present in healthy adipose tissue. However over the
last decade many have found evidence which strongly implicates an, as of yet,
unidentified self-antigen as the culprit behind T cell proliferation in healthy adipose
[142]. One such study demonstrated that CD4+ CD44+ CD62L- effector memory T
cells were present in the adipose tissue of healthy mice under normal dietary
conditions [39], suggesting that T cells had previously encountered and mounted
a response against some adipose-derived antigen.
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In a broader sense, low-level, self-antigen-induced T cell proliferation has
also been described before. Adoptively transferred naïve T cells can reconstitute
the entire T cell compartment in lymphopenic mice [188]. As they circulate these
cells begin to proliferate, eventually repopulating both central and peripheral
lymphatic tissues. Two distinct processes known as homeostatic and spontaneous
proliferation are behind this phenomenon [189, 190]. Homeostatic proliferation
occurs at a slower rate than canonical, foreign-antigen induced proliferation and
relies on the availability of cytokines such as IL-7 and IL-15 [189, 191]. Competition
for these resources is thought to be the signal that determines when the T cell
compartment within a particular niche is sufficiently repopulated [188].
Spontaneous proliferation, on the other hand, does not require any
secondary cytokine signal. This type of proliferation occurs at a much faster rate
than homeostatic proliferation, with cells dividing multiple times a day instead of
just once or twice every few days [190, 192]. The resulting T cells also differentiate
into various subsets of effector and memory T cells, capable of producing
inflammatory cytokines [40, 190].
Despite these major differences, antigen presentation and recognition are
required for both homeostatic and spontaneous T cell proliferation [188].
Reconstitution studies in both Rag knockout and germ-free mice indicate that
these processes are likely initiated by low affinity interactions with self-antigen
[191], presented by MHC-II on antigen presenting cells. Intriguingly, this bears a
striking resemblance to what occurs in the early stages of obesity, where resident
macrophages and dendritic cells present an unknown self-antigen to tissue
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resident CD4+ TEM, triggering a cascade of events that eventually leads to chronic
AT inflammation [193]. In this situation however, the high fat diet itself serves as
an additional inflammatory stimulus, augmenting the proliferative response of the
T cells. It is possible that in our MDSC depletion model, the T cells are responding
to this same self-antigen, but, in the absence of any other inflammatory pressure,
the size of their population is held in check by mechanisms similar to those which
control T cell expansion in models of homeostatic and spontaneous proliferation.
Regardless, these examples of non-foreign, antigen-induced T cell proliferation
demonstrate that T cell biology is far more nuanced than is often assumed.

Macrophage Dynamics
Besides controlling the T cell population and modulating ATM phenotype,
adipose resident MDSCs likely have beneficial interactions with other cells in the
tissue. To this end, we examined the expression of immunomodulatory genes in
whole adipose tissue and within the heterogeneous SVF isolate after acute MDSC
depletion. We discovered transcriptional changes (Figure 5.20) that, in some
cases, were unexpected given that expression of these same genes had not been
affected on the individual cell level in MDSCs, ATMs, and CD4 + TEM cells (Figure
5.15 & 5.19).
Importantly, our results do not indicate that aMDSCs are the ultimate
regulator of immune homeostasis in healthy adipose tissue. Instead they paint a
much more nuanced picture where the diverse immune cell network in AT is
constantly monitoring and responding to the dynamic challenges presented by this
metabolically active tissue. In this proposed working model, the loss of aMDSCs
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does not have catastrophic consequences, rather it destabilizes the entire network,
which then adjusts to counteract pro-inflammatory effects. Although this does
restore a semblance of normalcy to the tissue, there is evidence that this loss has
a lasting impact on the tissue, as we see with the continued increase in MHC-II
expression by ATMs and the progressive accumulation of CD4 + TEMs in the tissue,
despite there being a partial restoration of the aMDSC population.
Additionally, we observed a moderate negative correlation between the
number of adipose-resident MDSCs and the adiposity of that individual (Figure
5.8) suggesting that the loss of aMDSCs increases adipocyte lipid burden. Since
the animals in this study were only treated for one week, it is tempting to speculate
that long-term MDSC depletion may lead to increased weight gain on a normal
diet, when compared to untreated individuals. Furthermore, the alterations we
observed in the AT of αGr1-treated mice could exacerbate and accelerate the
development of metabolic consequences induced by high fat diet as these
symptoms are often preceded by macrophage repolarization and the infiltration of
activated T cells into the tissue [141]. A recent report found that MDSC depletion,
concurrent with 8 weeks of high fat diet, increased the severity of diet-induced
metabolic symptoms as well as TNFα transcription in the tissue compared to high
fat diet alone [194]. In our study, CD4+ TEM accumulated in the tissue of otherwise
healthy mice following MDSC depletion. If the Gr1 treatment used in this high fat
diet study elicited a similar response, then it's possible that the heightened
metabolic symptoms they observed in treated animals were at least partially due
to this augmented, initial T cell presence. Taken together with the results of our
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study, this suggests that the immune dysregulation we observed in healthy AT,
induced by MDSC depletion, may predispose this tissue to increased inflammatory
and metabolic consequences when challenged with a high fat diet.
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Figure 6.1: The Role of aMDSCs in Healthy Adipose Tissue. aMDSCs prevent
effector memory T cell proliferation (TEM) and promote the suppressive “M2”
phenotype of adipose tissue-resident macrophages (ATMs) in healthy adipose
tissue.
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Caveats to the αGr1 Model of MDSC Depletion
To investigate the importance of MDSCs in the homeostatic health of AT,
we employed the classic αGr1 antibody-mediated model of in vivo MDSC
depletion. This specific model and antibody clone have long been used to
interrogate the impact of MDSCs in various pathological settings. As discussed in
Chapter 5, Gr1 is expressed on multiple cell types; however, we were relatively
confident that the effects we observed in healthy adipose following antibody
treatment were instigated specifically by the loss of MDSCs and not the depletion
of other known cellular targets of this antibody such as neutrophils and some
subsets of CD8+ T cells (Figure 5.1). However, a recent study found that
eosinophils in an IL-5 rich microenvironment upregulated their surface expression
of Gr1 (as detected by the RB6-8C5 antibody clone) and Ly6G (as detected by the
1A8 antibody clone) [195]. Given that adipose resident eosinophils are recruited
into the tissue via IL-5 produced by ILC2s it’s likely that they also exhibit this
elevated Gr1/Ly6G expression. If this is the case, then it is possible that our
antibody treatment may have reduced or depleted eosinophils resident in adipose.
Their loss within the tissue could offer an alternate explanation for the αGr1induced changes we observe following acute treatment, since eosinophils are
known to promote the "M2"-like nature of ATMs [35]. The inadvertent depletion of
adipose eosinophils would not however lead to the rapid accumulation of CD4 +
TEM that we observe in both acutely and chronically treated mice.
One of our more perplexing observations was the partial restoration of
MDSCs in the spleens and adipose of mice treated for 4 weeks with αGr1. After
verifying that the antibody was not defective and switching to a weight-based
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dosing system, there seemed to be no clear explanation for the incomplete
depletion we were seeing in the 4 week treated mice. Looking back at the literature
we soon discovered that in most studies employing this depletion model animals
only receive one or two injections over a period ranging from 24 hours to 1 week.
Of the studies that used the antibody for more than a week [196-198], none
reported the reappearance of the Gr1+ cells they were targeting. In fact, when they
reported the efficacy of their MDSC depletion, if they did at all, they described
almost complete ablation of the Gr1+ population. Digging into the details of their
methodology, I uncovered a common flaw in the verification methods used in both
acute and chronic αGr1-mediated depletion studies. Often, investigators treat
animals with the RB6-8C5 clone of the αGr1 antibody, stain collected tissues with
a fluorophore conjugated version of this same clone, then declare that depletion
was successful when they don’t find any Gr1+ cells. This however fails to account
for epitope masking caused by the Gr1 treatment. Ideally the dose used to treat
the mice should be high enough to evenly distribute the antibody throughout their
tissues to reach as many of their Gr1 positive cells as possible. If this is the case,
then the surface of these cells should be saturated with antibody, making the
surface protein unavailable for binding by additional Gr1 antibodies used to stain
the tissue. Subsequent analysis via flow cytometry or microscopy would likely
underrepresent the true number of surviving MDSCs. Others used the 1A8 clone
of the Ly6G antibody to verify depletion [196, 198], however, previous staining or
treatment with αGr1 is known to block the Ly6G binding site.
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A small contingent of investigators have started to call for reform. In 2016
the Journal of Leukocyte Biology published a paper demonstrating that continued
treatment with the αGr1 antibody for more than 10 days appeared to induce
emergency myelopoiesis and severely diminished the antibody’s efficacy [170].
This “Ly-6G rebound” only became apparent when they stained tissues and cells
with a fluorophore conjugated secondary antibody against rat IgG2b, allowing them
to visualize Gr1+ cells without using the Gr1 antibody. An editorial published in the
same issue called for a reassessment of the long-term use of this model as well
as the ways in which we verify it [168, 170]. These warnings seem to have fallen
on deaf ears however as studies that verify Gr1-mediated depletion by staining for
Gr1+ cells continue to be published in journals at all levels.
We believe that the resurgence of MDSCs that we see in our 4 week treated
mice was not an artifact of insufficient treatment administration nor was it the result
of a defective αGr1 antibody, since we used a secondary, non-Gr1-associated
phenotype to characterize and quantify these cells (CD11b Hi Ly6CHi CD11cSSCLow). Additionally, our findings corroborate the “Ly-6G rebound effect”
described by Moses et al (2016), further supporting the need to carefully
reexamine how the αGr1 depletion model was used in the past and reassess how
it should be used in future studies.

Sexual Dimorphism in Healthy Adipose Immune Homeostasis
Like the majority of studies on the adipose tissue immune cell compartment
we almost exclusively collected data from male mice. However, there is a growing
body of literature that is beginning to reveal that anatomically equivalent adipose
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depots may behave differently in males and females [199-203]. For instance, there
is evidence that the immune "programming" in females is generally more
suppressive than in males [201, 203]. In the realm of adipose biology this means
that gonadal adipose depots tend to be less inflamed in female mice compared to
males when they are fed a high fat diet, containing fewer CD11c + ATMs and
expressing lower levels of proinflammatory genes such as Il1b and Nos2 [199].
This along with the differences we observed between males and females in our
pilot αGr1 depletion experiments (Figure 5.2) motivated our initial decision to
analyze adipose from both male and female mice. Although time restraints
eventually forced us to focus our investigations on males alone, we did obtain
partial datasets from both acute (N=4) and chronic (N=6) treatment groups, as well
as a small cohort of untreated controls (N=3).
Confirming what we observed in our pilot experiments, acute αGr1
treatment effectively eradicated MDSCs in the adipose of female mice [12.75 ± 2.7
x 103 aMDSCs/mL AT vs 0.44 ± 0.05 x 103 aMDSCs/mL AT] (Figure 6.2).
However, this population had completely rebounded in the adipose of chronically
treated mice [19.98 ± 2.5 x 103 aMDSC/mL AT] (Figure 6.2).
The frequency [1.5 ± 0.3% of AT SVF vs 2.23 ± 0.3% of AT SVF] and
absolute number [4.53 ± 1.3 x 104 CD4+ T cells/mL AT vs 7.37 ± 1.3 x 10 4 CD4+ T
cells/mL AT] of CD4+ T cells increased steadily over time (Figure 6.3 a), eventually
reaching statistical significance after 4 weeks of αGr1 treatment [2.84 ± 0.2% of
AT SVF; 11.21 ± 1.3 x 104 CD4+ T cells/mL AT], despite the MDSC population
being almost completely restored (Figure 6.3 a). It is likely that the acute treatment
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group would have reached statistical significance given a larger cohort of untreated
controls as adipose isolated from untreated males in this same experiment
contained an unusually high number of T cells, potentially due to the stress from a
recent room transfer within the animal housing facility. Similar to what we found in
males the majority of these cells belonged to the CD44 + CD62L- effector memory
subset of T cell (Data not shown). Unlike the males however CD69 expression on
these cells was unaffected by MDSC depletion (Figure 6.3 b).
Adipose from untreated female mice contained an almost negligible
population of CD8+ T cells [66 ± 50 CD8+ T cells / mL AT] which expanded in
response to MDSC depletion [1 Week: 832 ± 300 CD8+T cells/mL AT; 4 Week: 948
± 230 CD8+ T cells/mL AT] (Figure 6.3 c). The variation within each cohort
however is very large and the proportions of CD8 + T cells is relatively small, so it
is difficult to draw any reliable conclusions from this data.
We also examined the SVF from female mice for any charges in the resident
macrophage population. We found that acute and chronic MDSC depletion
induced a steady increase in the proportion [Untreated: 6.62 ± 0.8% of AT SVF;
Acute: 8.52 ± 0.9% of AT SVF; Chronic: 10.9 ± 0.8% of AT SVF] and absolute
number [Untreated: 21.3 ± 6.5 x 104 ATMs/mL AT; Acute: 27.5 ± 2.9 x 104
ATMs/mL AT; Chronic: 43.8 ± 6.2 x 10 4 ATMs/mL AT] of ATMs (Figure 6.4 a).
Both CD11c and MHC-II expression spiked following 1 week of treatment with
αGr1 [CD11c: 1.0 ± 0.004 vs 1.27 ± 0.04; MHC-II: 1.0 ± 0.05 vs 1.49 ± 0.1]. While
the relative MFI of these two surface markers drops slightly on the ATMs from 4-
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week treated females it does remain elevated compared to ATMs isolated from
untreated mice [CD11c: 1.12 ± 0.02; MHC-II: 1.33 ± 0.09] (Figure 6.4 b).
Although this dataset is incomplete, it does highlight some intriguing
differences between the adipose immune cell network in males and females. For
instance, the MDSC rebound in adipose of chronically treated females appears to
be more robust than what we observed in the males [156.7% vs 60.4% of
respective untreated aMDSC population]. A study looking at sexually dimorphic
MDSC responses in viral myocarditis found that females recruited a greater
number of M-MDSCs into the cardiac tissue than males and that these MDSCs
demonstrated superior suppressive abilities compared to the equivalent population
isolated from males [204]. One of the proposed mechanisms for the "Ly6G
rebound" is that the αGr1 antibody induces emergency myelopoiesis, a process
that can also recruit MDSCs to the site of chronic inflammation.
MDSC levels increase in both males and females in the myocarditis model.
However, females were able to more efficiently recruit highly suppressive MDSCs
into the inflamed tissue than males, which ultimately improved their survival over
males. It’s possible that we are seeing a similar differential response in the adipose
of male and female mice with the females demonstrating their ability to more
efficiently recruit MDSCs under myelopenic pressure.
Without functional or gene expression data we cannot really draw any solid
conclusions much beyond that there does appear to be a sexually dimorphic
response to MDSC depletion in otherwise healthy adipose tissue. Given our limited
picture it is tempting to speculate that the slower rate of T cell accumulation,
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reduced CD69 expression, and expanding ATM population we observed in
females are all related to their increased capacity to prevent visceral adipose
inflammation compared to males.
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Figure 6.2: αGr1 antibody treatment efficiently depletes MDSCs from adipose
tissue in female mice. (a, b) Healthy, 16 – 20-week old female, C57Bl/6 mice
were treated with αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Uterine horn
fat pads were collected one day after the final antibody injection. The frequency
(a) and absolute number (b) of aMDSCs (M-MDSCs + PMN-MDSCs) in AT SVF
from untreated (Blue) mice or animals receiving 1-week (Pink) or 4-weeks of αGr1
treatment (Green). Bars depict the mean of 3 untreated, 4 1-week αGr1-treated,
or 6 4-week αGr1-treated mice. Differences between αGr1-treated and untreated
animals determined using a Student’s t-test. *: P < 0.05.
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Figure 6.3: MDSC depletion increases the numbers of T cells in healthy
female adipose tissue. Healthy, 16 – 20-week old female C57Bl/6 mice were
treated with αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Uterine horn fat
pads were collected one day after the final antibody injection. (a) Frequency (Left)
and absolute number (Right) of CD4+ T cells in the SVF of αGr1-treated and
untreated mice. (b) The geometric mean fluorescence intensity (MFI) of CD69
expression on CD44+ CD62L- TEM in the SVF of either 1-week (Pink) or 4-week
(Green) αGr1-treated mice relative to untreated controls (Blue). (c) Frequency
(Left) and absolute number (Right) of CD8+ T cells in the SVF of αGr1-treated and
untreated mice. Bars depict the mean of 3 untreated (Blue), 4 1-week αGr1-treated
(Pink), or 6 4-week αGr1-treated mice (Green). (a – c) Data pooled from 3
independent experiments. Error bars represent SEM. Differences between αGr1treated and untreated animals determined using a Student’s t-test. *: P < 0.05 and
NS: P > 0.05.
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Figure 6.4: αGr1 treatment augments the number of macrophages & changes
their surface marker expression in female adipose tissue. Healthy, 16 – 20week old female C57Bl/6 mice were treated with αGr1 (15 μg/g) every 3 – 4 days
for 1 or 4 weeks. Uterine horn fat pads were collected one day after the final
antibody injection. (a) Frequency (Upper) and absolute number (Lower) of CD11b +
F4/80+ MHC-II+ adipose tissue-resident macrophages (ATMs) in the total AT SVF.
(b) The geometric mean fluorescence intensity (MFI) of CD11c (Blue) & MHC-II
(Pink) on CD11b+ F4/80+ MHC-II+ ATMs following 1 or 4 weeks of αGr1 treatment.
Data pooled from 3 independent experiments. Error bars represent SEM.
Differences between αGr1-treated and untreated animals determined using a
Student’s t-test. *: P < 0.05 and NS: P > 0.05.
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Translational & Therapeutic Potential
Recently, one group found that while the overall percentage of CD45 +
adipose stromal cells was similar in mice, non-human primates, and humans, the
proportions of various immune cell subsets within that CD45 + population differed
greatly from one species to the next [205]. Their work raised major concerns
regarding the translatability of adipose biology studies from the bench into the clinic
since the immune cell compartment in this tissue appeared to vary so widely even
between different strains of mice. In our studies we addressed these concerns on
two fronts. First, we sought to determine whether the presence of aMDSCs in
healthy mice was consistent between strains or if it was an artifact of our specific
model. To this end we performed a cursory analysis of the immune cell
compartment in four male Balb/c mice using our established myeloid and T cell
staining panels. Similar to the study referenced above, we found that there was no
difference in the total number of adipose stromal cells [22.7 ± 2.0 x 10 5 cells/mL
AT vs 24.7 ± 2.4 x 105 cells/mL AT] between the two mouse strains (Figure 6.5 a).
There was also no difference in the frequency [0.575 ± 0.06% of AT SVF vs 0.419
± 0.06% of AT SVF] or absolute number [1.57 ± 0.2 x10 4 cells/mL AT vs 1.69 ± 0.7
x 104 cells/mL AT] of aMDSCs in adipose from the C57Bl/6 and Balb/c mice
(Figure 6.5 b). The adipose from Balb/c mice tended to contain more CD301 +
ATMs than C57Bl/6 mice [36.23 ± 3.7 x 10 4 cells/mL AT vs 47.29 ± 14.0 x 104
cells/mL AT], but this difference was not significant (Figure 6.5 b). However, CD4+
T cells did make up a significantly larger proportion of the AT SVF from the Balb/c
mice compared to the C57Bl/6 mice [1.82 ± 0.4% of AT SVF vs 0.86 ± 0.07% of
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AT SVF] and, intriguingly, a significantly smaller percentage of this population were
CD44+ CD62L- TEM [64.4 ± 5.8% of CD4+ SVF cells vs 97.4 ± 0.4% of CD4+ SVF
cells] (Figure 6.5 c – d).
Our second way of addressing the translatability of our work was by
characterizing the stromal cells in samples of human adipose tissue. Samples
were obtained from patients undergoing routine liposuction procedures and were
processed in much the same way as our murine adipose samples. Cells were then
stained and analyzed using flow cytometry. Despite being harvested from a
subcutaneous, instead of visceral, adipose depot, we identified two myeloid cell
populations that expressed surface markers characteristic of human M-MDSCs
(CD11b+ CD33+ HLA-DR- CD14+) and PMN-MDSCs (CD11b+ HLA-DR- CD14CD15+) [100] (Figure 6.6 a – b). Unfortunately, due to time and equipment access
restrictions we were not able to perform the requisite in vitro functional assays with
these cells and are therefore unable to draw any concrete conclusions regarding
their identity as true MDSCs. However, adipose in some form or another is highly
conserved evolutionarily and from the fat bodies found in insects to the various
adipose depots in mammals, this metabolically dynamic tissue is consistently
intertwined with the regulatory branch of the immune system [185, 206, 207]. As
such it is likely that the two myeloid cell populations, which we identified in human
adipose, are indeed immunosuppressive MDSCs, involved in moderating adipose
immune homeostasis.
In addition to our characterization data, the findings from clinical trials of
autologous SVF cellular therapies provide further evidence supporting the
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presence of MDSCs in human adipose. SVF-based therapies have a potent antiinflammatory effect when they are used to treat allogeneic transplant rejection.
Many aspects of this response such as increased angiogenesis or enriched
populations of TRegs and “M2” polarized macrophages have also been described in
clinical trials where in vitro generated MDSCs alone are used to treat rejection [91,
208, 209]. It is important to note however that the overall anti-inflammatory effects
of SVF-based therapies most likely results from the combined efforts of all of the
AT-resident immune cells, as their collective crosstalk preserves the suppressive
phenotypes of each individual cell once they are introduced into a pro-inflammatory
microenvironment.
Moreover, MDSCs resident in healthy human adipose tissue could
represent a new therapeutic target for diabetes and obesity. These diseases are
characterized by a disruption in the anti-inflammatory adipose microenvironment,
mediated by the infiltration of inflammatory immune cells into the tissue. Studies
have already demonstrated that injections of culture derived MDSCs into obese
mice increased insulin sensitivity and delayed the onset of metabolic syndromes
[129]. Determining whether MDSCs play a significant part in maintaining immune
homeostasis in human AT could help us develop new therapies that designed to
promote and re-establish homeostatic conditions in obese adipose where the
immunosuppressive cell network has been significantly degraded.
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Figure 6.5: Flow cytometric characterization of healthy adipose tissue from
Balb/c mice. (a) The absolute number of SVF cells obtained (normalized to the
volume of adipose tissue harvested) from either C57Bl/6 (Blue) or Balb/c (Pink)
mice. (b) The absolute number of aMDSCs and CD11b + F4/80+ MHC-II+
macrophages (ATMs) in the adipose SVF of C57Bl/6 (Blue) or Balb/c (Pink) mice.
(c) The frequency (Left) and absolute number (Right) of CD4+ T cells in the SVF
of αGr1-treated and untreated mice. (d) Frequency of CD4+ SVF cells that were
CD44+ CD62L- TEM. (a – d) Bars depict the mean of 11 C57Bl/6 or 4 Balb/c mice.
Error bars denote the SEM. Differences between the C57Bl/6 and Balb/c mice
determined using a Student’s t-test. *: P < 0.05 and NS: P > 0.05.
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Figure 6.6: Flow cytometric characterization of healthy human adipose
tissue. (a) Representative dot plots depicting the MDSC characterization strategy
used for human adipose tissue stromal vascular fraction cells (SVF). (b) The
frequency of various immune cell populations in human adipose SVF. Each circle
represents an individual patient and the horizontal bars represent the mean of the
data collected from 6-7 patients.
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FUTURE DIRECTIONS
This study uncovered an intriguing new layer of the immune cell network in
healthy adipose tissue; however, there are a few remaining questions that we were
unable to fully investigate.

How do adipose-resident MDSCs prevent CD4 + TEM proliferation under
healthy conditions?
Peroxynitrite-mediated nitrosylation of T cell receptors (TCR) or MHC-II
interferes in the antigen recognition process and is also one of the more indirect
mechanisms by which tumor-associated MDSCs modulate T cell responses [157].
These misfolded proteins result from interactions between radical nitrogen species
and exposed tyrosine residues on the targeted protein. We hypothesized that
nitrosylation of antigen recognition or presentation machinery could explain the
delayed onset of aMDSC-mediated immune modulation, since the suppressive
effects of this process on T cell proliferation increases with increased exposure to
radical nitrogen species. Unfortunately, we were only able to perform one pilot
experiment on the SVF from a healthy mouse, but this did yield promising results.
Using flow cytometry, we found that the CD4+ and CD8+ adipose tissue T cells did
have more nitrosylated tyrosine residues on their surface than T cells in the
spleens of these mice (Figure 6.7).
Although far from conclusive, it is tempting to speculate that this
nitrosylation was a direct result of their proximity to aMDSCs. If time had allowed
it would definitely have been worthwhile to investigate the nitrosylation state of the
CD301+ ATMs isolated from the SVF of αGr1-treated mice as I suspect that the
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sudden reinstatement of functional antigen presentation machinery may be a large
factor in the rapid accumulation of T cells following in vivo MDSC depletion.
Additional support for this hypothesis can be found in the literature on T cell and
macrophage dynamics in the early stages of obesity development. These studies
have found that the initial accumulation of CD4 + inflammatory T cells is triggered
by an endogenous adipose antigen [210] that is presented to these ATMs in an
MHCII-dependent fashion [142]. If we plug our observations from the MDSC
depletion experiments into this working model, it would suggest that aMDSCs in
healthy adipose modulate the functionality of antigen presentation machinery on
AT macrophages, impeding their ability to inadvertently reactivate AT resident T EM.
To determine if aMDSC-mediated nitrosylation of antigen presenting and
recognizing proteins prevents TEM activation and proliferation, we would expand
the preliminary line of investigation to include αGr1 depletion experiments for one
or four weeks. SVF cells would be stained with T cell and macrophage markers
along with the N-tyrosine antibody used in our pilot experiments. Analyzing these
samples on an Image Stream would allow us to detect colocalization of nitrosylated
tyrosine residues on T cell receptors and MHC proteins. Additional staining could
be used to assess whether MDSC-depletion increases surface expression of CD3ζ
or IL-2R on adipose tissue T cells, as these two proteins are directly involved in
antigen-mediated responses and lose functionality as a result of aMDSC
nitrosylation.
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Figure 6.7: Macrophages, but not T cells have nitrosylated surface proteins
in healthy adipose SVF. (a) Contour plot comparing CD4 and CD8 expression on
nitrosylated tyrosine (N-tyrosine) positive SVF cells (Blue) versus the whole SVF
isolate (Pink). (b) Overlaid histograms showing N-tyrosine on the surface of CD4 +
SVF T cells (Blue). Unstained SVF T cells (Pink) back-gated based on similar size
and granularity (FSC-A vs SSC-A) to CD4+ SVF. (c) Contour plot comparing
CD11b and CD301 expression on N-tyrosine positive SVF cells (Blue) versus the
whole SVF isolate (Pink). (d) Overlaid histograms showing N-tyrosine on the
surface of CD301+ adipose tissue macrophages (ATMs) (Blue). Unstained SVF
(Pink) back-gated based on similar size and granularity (FSC-A vs SSC-A) to
CD11b+ CD301+ ATMs.

167

What recruits MDSCs to healthy adipose tissue?
The current thinking on MDSC genesis is that TLR activation recruits
circulating monocytes into the tissue or tumor, where they encounter a second TLR
agonist, in addition to immunomodulatory signals such as IL-10 and TGFβ. This
combination of pro-and anti-inflammatory stimuli "reprograms" the monocyte,
causing it to acquire immune suppressive functions [93]. In vivo, conditions such
as these typically occur at sites of chronic inflammation where pro-inflammatory
Type I responses react to an insult, while tissue remodeling Type II responses
attempt to repair and prevent further damage to surrounding tissue. As discussed
in the Introduction, a surprisingly similar microenvironmental setting can be found
in healthy AT (Figure 6.8). This tissue is constantly remodeling to accommodate
for fluctuations in adipocyte size as they store and release lipid [13]. The TNFαmediated degradation of the extracellular matrix required for these dynamic
structural changes [13] may provide a constitutive source of TLR agonists such as
biglycan and decorin [15] which are recognized by TLRs 2 and 4. Once recruited
into the tissue, circulating monocytes would encounter the suppressive network of
AT-resident immune cells, including aMDSCs, which would provide the secondary
immunomodulatory signals, such as IL-10, IL-13, and TGFβ, needed to promote
their reprogramming [29, 154]. This homeostatic oscillation between acute
inflammation and its rapid resolution creates an ideal niche for a population of
tissue resident MDSCs to thrive.
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Figure 6.8: Proposed model for MDSC recruitment into healthy adipose
tissue.
1) Adipocyte lipolysis or lipogenesis induces the breakdown of the extracellular
matrix (ECM). By-products of ECM remodeling can trigger toll-like receptors on
circulating monocytes, recruiting them into the tissue.
2) Monocytes encounter pro-inflammatory signals from further TLR stimulation or
produced by effector memory T cells (TEM).
3) The abundance of immunomodulatory cytokines found in healthy adipose
tissue provide concurrent anti-inflammatory signals to the monocyte.
4) The combination of pro- and anti-inflammatory stimuli reprograms the
monocyte to adopt a suppressive MDSC phenotype.
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What is the relationship between MDSCs and metabolic disease?
For almost a decade the relationship between MDSCs and obesity has been
a subject of interest for those investigating alternative therapies for metabolic
disease [97, 129, 130, 211]. Our work has introduced another layer to this by
demonstrating that MDSCs are constitutively present in healthy adipose tissue and
not just the inflamed adipose of obesity as described by others. However, if these
cells accumulate during obesity and the severity of metabolic symptoms negatively
correlates with the number of MDSCs in the tissue [129], then why does adipose
become inflamed in the first place and why does chronic high fat diet exacerbate
this inflammation even as the MDSC population expands?
One possibility is that the increasingly pro-inflammatory conditions that
develop in adipose tissue during high fat diet force their differentiation into “M1”type macrophages. Several lines of evidence from tumor and adipose biology
support this consideration. First, the repolarization and forced differentiation of
MDSCs into pro-inflammatory macrophages and dendritic cells has been
described as a possible strategy in overcoming their potent suppression of antitumor immune responses [212]. Second, further supporting this idea is the
accumulation of CD11c+ monocyte derived “M1” macrophages in obese adipose
tissue [20]. Pro-inflammatory cues recruit circulating monocytes into the adipose
which then differentiate into mature antigen presenting cells, capable of inciting
inflammatory T cell responses. Third, these same factors can cause normally
suppressive, ATMs to shift towards an “M1” phenotype themselves [29]. This
indicates that pro-inflammatory cues within the adipose microenvironment recruit
inflammatory cells and actively affect the functional phenotypes of both recruited
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and tissue resident cells. Altogether these studies demonstrate the functional
plasticity of MDSCs as well as their sensitivity to shifts in microenvironmental cues.
Given MDSC plasticity, it is likely that chronic exposure to the pro-inflammatory
microenvironment within obese adipose tissue ultimately leads to their
differentiation into “M1” macrophages further propagating obesity-induced
inflammation.
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